Skip navigation

St. John's wort


What is it?

St. John’s wort is an herb. Its flowers and leaves are used to make medicine.

St. John’s wort is most commonly used for depression and conditions that sometimes go along with depression such as anxiety, tiredness, loss of appetite and trouble sleeping. There is some strong scientific evidence that it is effective for mild to moderate depression.

Other uses include heart palpitations, moodiness and other symptoms of menopause, attention deficit-hyperactivity disorder (ADHD), obsessive-compulsive disorder (OCD), and seasonal affective disorder (SAD).

St. John’s wort has been tried for exhaustion, stop-smoking help, fibromyalgia, chronic fatigue syndrome (CFS), migraine and other types of headaches, muscle pain, nerve pain, and irritable bowel syndrome. It is also used for cancer, HIV/AIDS, and hepatitis C.

An oil can be made from St. John’s wort. Some people apply this oil to their skin to treat bruises and scrapes, inflammation and muscle pain, first degree burns, wounds, bug bites, hemorrhoids, and nerve pain. But applying St. John’s wort directly to the skin is risky. It can cause serious sensitivity to sunlight.

St. John’s wort is native to Europe but is commonly found in the US and Canada in the dry ground of roadsides, meadows, and woods. Although not native to Australia and long considered a weed, St. John’s wort is now grown there as a crop. Today, Australia produces 20 percent of the world’s supply.

The use of St. John’s wort dates back to the ancient Greeks. Hippocrates recorded the medical use of St. John’s wort flowers. St. John’s wort was given its name because it blooms about June 24th, the birthday of John the Baptist. “Wort” is an old English word for plant.

France has banned the use of St. John’s wort products. The ban appears to be based on a report issued by the French Health Product Safety Agency warning of significant interactions between St. John’s wort and some medications. Several other countries, including Japan, the United Kingdom, and Canada, are in the process of including drug-herb interaction warnings on St. John’s wort products.

The active ingredients in St. John’s wort can be deactivated by light. That’s why you will find many products packaged in amber containers. The amber helps, but it doesn’t offer total protection against the adverse effects of light.

How effective is it?

Natural Medicines Comprehensive Database rates effectiveness based on scientific evidence according to the following scale: Effective, Likely Effective, Possibly Effective, Possibly Ineffective, Likely Ineffective, Ineffective, and Insufficient Evidence to Rate.

The effectiveness ratings for ST. JOHN'S WORT are as follows:

Likely effective for...

  • Mild to moderate depression. Taking St. John’s wort extracts improves mood, and decreases anxiety and insomnia related to depression. It seems to be about as effective in treating depression as many prescription drugs. In fact, clinical guidelines from the American College of Physicians-American Society of Internal Medicine suggest that St. John’s wort can be considered an option along with antidepressant medications for short-term treatment of mild depression. However, since St. John’s wort does not appear to be more effective or significantly better tolerated than antidepressant medications, and since St. John’s wort causes many drug interactions, the guidelines suggest it might not be an appropriate choice for many people, particularly those who take other medications. St. John’s wort might not be as effective for more severe cases of depression.

Possibly effective for...

  • Menopausal symptoms. Some research shows that a combination of St. John’s wort plus black cohosh can help improve menopausal symptoms.
  • The conversion of mental experiences or states into bodily symptoms (somatization disorder). Treatment with St. John’s wort seems to reduce symptoms after 6 weeks of treatment.
  • Wound healing. Some research shows that applying a specific St. John’s wort ointment (Gol-Daru Company) three times daily for 16 days improves wound healing and reduces scar formation after a cesarean section.

Possibly ineffective for...

  • Attention deficit-hyperactivity disorder (ADHD). Taking a St. John’s wort extract for 8 weeks does not seem to improve symptoms of ADHD in children ages 6-17 years.
  • Hepatitis C virus (HCV) infection.
  • HIV/AIDS.
  • Irritable bowel syndrome (IBS).
  • Pain conditions related to diabetes (polyneuropathy.

Insufficient evidence to rate effectiveness for...

  • Obsessive compulsive disorder (OCD). There is conflicting evidence about the effectiveness of St. John’s wort for OCD. The reason for contradictory findings could be due to differences in study design, differences in the St. John’s wort products used, or other factors.
  • Premenstrual syndrome (PMS). There is preliminary evidence that St. John’s wort might help reduce PMS symptoms, by even as much as 50% in some women.
  • Seasonal affective disorder (SAD). Early studies suggest that St. John’s wort might help SAD. It appears to improve symptoms of anxiety, decreased sex drive, and sleep disturbances associated with SAD. It is useful alone or in combination with light therapy.
  • Smoking cessation. Research to date suggests that taking a specific St. John’s wort extract (LI-160, Lichtwer Pharma US) 300 mg once or twice daily starting 1 week before and continuing for 3 months after quitting smoking does not improve long-term quit rates.
  • Stomach upset.
  • Bruises.
  • Skin conditions.
  • Migraine headache.
  • Nerve pain.
  • Sciatica.
  • Excitability.
  • Fibromyalgia.
  • Chronic fatigue syndrome (CFS).
  • Muscle pain.
  • Cancer.
  • Weight loss.
  • Other conditions.
More evidence is needed to rate St. John’s wort for these uses.

How does it work?

Return to top
For a long time, investigators thought a chemical in St. John’s wort called hypericin was responsible for its effects against depression. More recent information suggests another chemical, hyperforin, may play a larger role in depression. Hypericin and hyperforin act on chemical messengers in the nervous system that regulate mood.

Are there safety concerns?

Return to top
St. John’s wort is LIKELY SAFE for most people when taken by mouth short-term. It can cause some side effects such as trouble sleeping, vivid dreams, restlessness, anxiety, irritability, stomach upset, fatigue, dry mouth, dizziness, headache, skin rash, diarrhea, and tingling. Take St. John’s wort in the morning or lower the dose if it seems to be causing sleep problems.

St. John’s wort seems to be safe when used in children under 12 years of age for up to 6 weeks.

However, St. John’s wort is POSSIBLY UNSAFE when taken by mouth in large doses. It might cause severe reactions to sun exposure. Wear sun block outside, especially if you are light-skinned.

Not enough is known about the safety of St. John’s wort when it is applied to the skin. To be safe, don’t use it topically.

St. John’s wort interacts with many drugs (see the section below). Let your healthcare provider know if you want to take St. John’s wort. Your healthcare provider will want to review your medications to see if there could be any problems.

Special precautions & warnings:

Pregnancy and breast-feeding: St. John’s wort is POSSIBLY UNSAFE when taken during pregnancy. There is some evidence that it can cause birth defects in unborn rats. No one yet knows whether it has the same effect in unborn humans. Nursing infants of mothers who take St. John’s wort can experience colic, drowsiness, and listlessness. Until more is known, don’t use St. John’s wort if you are pregnant or breast-feeding.

Infertility: There are some concerns that St. John’s wort might interfere with conceiving a child. If you are trying to conceive, don’t use St. John’s wort, especially if you have known fertility problems.

Attention deficit-hyperactivity disorder (ADHD): There is some concern that St. John’s wort might worsen symptoms of ADHD, especially in people taking the medication methylphenidate for ADHD. Until more is known, don’t use St. John’s wort if you are taking methylphenidate.

Bipolar disorder: People with bipolar disorder cycle between depression and mania, a state marked by excessive physical activity and impulsive behavior. St. John’s wort can bring on mania in these individuals and can also speed up the cycling between depression and mania.

Major depression: In people with major depression, St. John’s wort might bring on mania, a state marked by excessive physical activity and impulsive behavior.

Schizophrenia: St. John’s wort might bring on psychosis in some people with schizophrenia.

Alzheimer’s disease: There is concern that St. John’s wort might contribute to dementia in people with Alzheimer’s disease.

Anesthesia and surgery: Use of anesthesia in people who have used St. John’s wort for six months may lead to serious heart complications during surgery. Stop using St. John’s wort at least two weeks before a scheduled surgery.

Are there interactions with medications?

Return to top

Major

Do not take this combination.

Alprazolam (Xanax)
Alprazolam (Xanax) is commonly used for anxiety. The body breaks down alprazolam (Xanax) to get rid of it. St. John's wort can increase how fast the body gets rid of alprazolam (Xanax). Taking St. John's wort along with alprazolam (Xanax) might decrease the effectiveness of alprazolam (Xanax).

Birth control pills (Contraceptive drugs)
Some birth control pills contain estrogen. The body breaks down the estrogen in birth control pills to get rid of it. St. John's wort might increase the breakdown of estrogen. Taking St. John's wort along with birth control pills might decrease the effectiveness of birth control pills. If you take birth control pills along with St. John's wort, use an additional form of birth control such as a condom.

Some birth control pills include ethinyl estradiol and levonorgestrel (Triphasil), ethinyl estradiol and norethindrone (Ortho-Novum 1/35, Ortho-Novum 7/7/7), and others.

Digoxin (Lanoxin)
Digoxin (Lanoxin) helps the heart beat more strongly. St. John's wort might decrease how much digoxin (Lanoxin) the body absorbs. By decreasing how much digoxin (Lanoxin) the body absorbs, St. John's wort might decrease the effects of digoxin (Lanoxin).

Fenfluramine (Pondimin)
Fenfluramine (Pondimin) increases a chemical in the brain. This chemical is called serotonin. St. John's wort also increases serotonin. Taking fenfluramine with St. John's wort might cause there to be too much serotonin. This could cause serious side effects including heart problems, shivering, nausea, headache, and anxiety.

Imatinib (Gleevec)
The body breaks down imatinib (Gleevec) to get rid of it. St. John's wort might increase how quickly the body gets rid of imatinib (Gleevec). Taking St. John's wort along with imatinib (Gleevec) might decrease the effectiveness of imatinib (Gleevec). Do not take St. John's wort if you are taking imatinib (Gleevec).

Irinotecan (Camptosar)
Irinotecan (Camptosar) is used to treat cancer. The body breaks down irinotecan (Camptosar) to get rid of it. St. John's wort might increase how fast the body breaks down irinotecan (Camptosar) and decrease the effectiveness of irinotecan (Camptosar).

Medications changed by the liver (Cytochrome P450 2C19 (CYP2C19) substrates)
Some medications are changed and broken down by the liver. St. John's wort might increase how quickly the liver breaks down some medications. Taking St. John's wort along with some medications that are broken down by the liver can decrease the effectiveness of your medication. Before taking St. John's wort, talk to your healthcare provider if you take any medications that are changed by the liver.

Some medications that are changed by the liver include amitriptyline (Elavil), carisoprodol (Soma), citalopram (Celexa), diazepam (Valium), lansoprazole (Prevacid), omeprazole (Prilosec), phenytoin (Dilantin), warfarin, and many others.

Medications changed by the liver (Cytochrome P450 3A4 (CYP3A4) substrates)
Some medications are changed and broken down by the liver. St. John's wort might increase how quickly the liver breaks down some medications. Taking St. John's wort along with some medications that are broken down by the liver can decrease the effectiveness of some medications. Before taking St. John's wort talk to your healthcare provider if you are taking any medications that are changed by the liver.

Some medications changed by the liver include lovastatin (Mevacor), ketoconazole (Nizoral), itraconazole (Sporanox), fexofenadine (Allegra), triazolam (Halcion), and many others.

Medications for HIV/AIDS (Nonnucleoside Reverse Transcriptase Inhibitors (NNRTIs))
The body breaks down medications used for HIV/AIDS. St. John's wort can increase how quickly the body breaks down these medications. Taking St. John's wort might decrease how well some medications used for HIV/AIDS work.

Some of these medications used for HIV/AIDS include nevirapine (Viramune), delavirdine (Rescriptor), and efavirenz (Sustiva).

Medications for HIV/AIDS (Protease Inhibitors)
The body breaks down medications used for HIV/AIDS to get rid of them. Taking St. John's wort might increase how quickly the body breaks down these medications. This could decrease the effectiveness of some medications used for HIV/AIDS.

Some of these medications used for HIV/AIDS include amprenavir (Agenerase), nelfinavir (Viracept), ritonavir (Norvir), and saquinavir (Fortovase, Invirase).

Medications moved by pumps in cells (P-Glycoprotein Substrates)
Some medications are moved by pumps in cells. St. John's wort can make these pumps more active and decrease how much of some medications get absorbed by the body. This might decrease the effectiveness of some medications.

Some medications that are moved by these pumps include etoposide, paclitaxel, vinblastine, vincristine, vindesine, ketoconazole, itraconazole, amprenavir, indinavir, nelfinavir, saquinavir, cimetidine, ranitidine, diltiazem, verapamil, corticosteroids, erythromycin, cisapride (Propulsid), fexofenadine (Allegra), cyclosporine, loperamide (Imodium), quinidine, and others.

Mephenytoin (Mesantoin)
Mephenytoin (Mesantoin) is changed and broken down by the body. St. John's wort might increase how quickly this medication is broken down by the body. Do not take St. John's wort if you are taking mephenytoin (Mesantoin).

Phenobarbital (Luminal)
The body breaks down phenobarbital (Luminal) to get rid of it. St. John's wort might increase how quickly the body breaks down phenobarbital. This could decrease how well phenobarbital works.

Phenprocoumon
The body breaks down phenprocoumon to get rid of it. St. John's wort increases how quickly the body breaks down phenprocoumon. This decreases the effectiveness of phenprocoumon.

Phenytoin (Dilantin)
The body breaks down phenytoin (Dilantin) to get rid of it. St. John's wort might increase how quickly the body breaks down phenytoin. Taking St. John's wort and taking phenytoin (Dilantin) might decrease the effectiveness of phenytoin (Dilantin) and increase the possibility of seizures.

Tacrolimus (Prograf, Protopic)
The body breaks down tacrolimus (Prograf, Protopic) to get rid of it. St. John's wort can increase how quickly the body breaks down tacrolimus (Prograf, Protopic). This can cause tacrolimus (Prograf, Protopic) to be less effective.

Warfarin (Coumadin)
Warfarin (Coumadin) is used to slow blood clotting. The body breaks down warfarin (Coumadin) to get rid of it. St. John's wort might increase the breakdown and decrease the effectiveness of warfarin (Coumadin). Decreasing the effectiveness of warfarin (Coumadin) might increase the risk of clotting. Be sure to have your blood checked regularly. The dose of your warfarin (Coumadin) might need to be changed.

Moderate

Be cautious with this combination.

Aminolevulinic acid
Aminolevulinic acid can make your skin sensitive to the sunlight. St. John's wort might also increase your sensitivity to sunlight. Taking St. John's wort along with aminolevulinic acid might increase the chances of sunburn, blistering or rashes on areas of skin exposed to sunlight. Be sure to wear sunblock and protective clothing when spending time in the sun.

Amitriptyline (Elavil)
The body breaks down amitriptyline (Elavil) to get rid of it. St. John's wort can increase how quickly the body gets rid of some medications. St. John's wort might decrease the effectiveness of amitriptyline (Elavil) by increasing how quickly the body breaks down amitriptyline (Elavil).

Clopidogrel (Plavix)
The body breaks down clopidogrel (Plavix) to a chemical that decreases blood clotting in the body. Taking St. John's wort along with clopidogrel (Plavix) might increase how well the body breaks down clopidogrel (Plavix) and decrease blood clotting too much.

Cyclosporine (Neoral, Sandimmune)
The body breaks down cyclosporine (Neoral, Sandimmune) to get rid of it. St. John's wort might increase how quickly the body breaks down cyclosporine (Neoral, Sandimmune). By increasing the breakdown of cyclosporine (Neoral, Sandimmune) St. John's wort might decrease the effectiveness of cyclosporine (Neoral, Sandimmune). Do not take St. John's wort if you are taking cyclosporine (Neoral, Sandimmune).

Dextromethorphan (Robitussin DM, and others)
St. John's wort can affect a brain chemical called serotonin. Dextromethorphan (Robitussin DM, others) can also affect serotonin. Taking St. John's wort along with dextromethorphan (Robitussin DM, others) might cause too much serotonin in the brain and serious side effects including heart problems, shivering, and anxiety. Do not take St. John's wort if you are taking dextromethorphan (Robitussin DM, and others).

Fexofenadine (Allegra)
The body breaks down fexofenadine (Allegra) to get rid of it. St. John's wort might decrease how quickly the body gets rid of fexofenadine. This could cause fexofenadine (Allegra) to stay in the body too long. This could lead to increased effects and side effects of fexofenadine (Allegra).

Medications changed by the liver (Cytochrome P450 1A2 (CYP1A2) substrates)
Some medications are changed and broken down by the liver. St. John's wort might increase how quickly the liver breaks down some medications. Taking St. John's wort along with some medications that are changed by the liver can decrease the effectiveness of some medications. Before taking St. John's wort, talk to your healthcare provider if you take any medications that are changed by the liver.

Some of these medications that are changed by the liver include clozapine (Clozaril), cyclobenzaprine (Flexeril), fluvoxamine (Luvox), haloperidol (Haldol), imipramine (Tofranil), mexiletine (Mexitil), olanzapine (Zyprexa), pentazocine (Talwin), propranolol (Inderal), tacrine (Cognex), zileuton (Zyflo), zolmitriptan (Zomig), and others.

Medications changed by the liver (Cytochrome P450 2C9 (CYP2C9) substrates)
Some medications are changed and broken down by the liver. St. John's wort might increase how quickly the liver breaks down some medications. Taking St. John's wort along with some medications that are broken down by the liver can decrease the effectiveness of your medication. Before taking St. John's wort, talk to your healthcare provider if you take any medications that are changed by the liver.

Some medications that are changed by the liver include amitriptyline (Elavil), diazepam (Valium), zileuton (Zyflo), celecoxib (Celebrex), diclofenac (Voltaren), fluvastatin (Lescol), glipizide (Glucotrol), ibuprofen (Advil, Motrin), irbesartan (Avapro), losartan (Cozaar), phenytoin (Dilantin), piroxicam (Feldene), tamoxifen (Nolvadex), tolbutamide (Tolinase), torsemide (Demadex), warfarin (Coumadin), and others.

Medications for depression (Antidepressant drugs)
St. John's wort increases a brain chemical called serotonin. Some medications for depression also increase the brain chemical serotonin. Taking St. John's wort along with these medications for depression might increase serotonin too much and cause serious side effects including heart problems, shivering, and anxiety. Do not take St. John's wort if you are taking medications for depression.

Some of these medications for depression include fluoxetine (Prozac), paroxetine (Paxil), sertraline (Zoloft), amitriptyline (Elavil), clomipramine (Anafranil), imipramine (Tofranil), and others.

Medications for depression (MAOIs)
St. John's wort increases a chemical in the brain. This chemical is called serotonin. Some medications used for depression also increase serotonin. Taking St. John's wort with these medications used for depression might cause there to be too much serotonin. This could cause serious side effects including heart problems, shivering, and anxiety.

Some of these medications used for depression include phenelzine (Nardil), tranylcypromine (Parnate), and others.

Medications for migraine headaches ("Triptans")
Some medications for migraine headaches can affect a chemical in the brain called serotonin. St. John's wort can also affect serotonin. Taking St. John's wort along with some medications for migraine headache might cause too much serotonin in the brain and serious side effects including confusion, shivering, stiff muscles, and other side effects.

Some medications for migraine headache include frovatriptan (Frova), naratriptan (Amerge), rizatriptan (Maxalt), sumatriptan (Imitrex), and zolmitriptan (Zomig).

Medications for pain (Narcotic drugs)
The body breaks down some medications for pain to get rid of them. St. John's wort might decrease how fast the body gets rid of some medications for pain. By decreasing how fast the body gets rid of some medications for pain, St. John's wort might increase the effects and side effects of some medications for pain.

Some medications for pain include meperidine (Demerol), hydrocodone, morphine, oxycodone (OxyContin), and many others.

Medications that increase sensitivity to sunlight (Photosensitizing drugs)
Some medications can increase sensitivity to sunlight. St. John's wort might also increase your sensitivity to sunlight. Taking St. John's wort along with medications that increase sensitivity to sunlight could increase the chances of sunburn, blistering or rashes on areas of skin exposed to sunlight. Be sure to wear sunblock and protective clothing when spending time in the sun.

Some drugs that cause photosensitivity include amitriptyline (Elavil), Ciprofloxacin (Cipro), norfloxacin (Noroxin), lomefloxacin (Maxaquin), ofloxacin (Floxin), levofloxacin (Levaquin), sparfloxacin (Zagam), gatifloxacin (Tequin), moxifloxacin (Avelox), trimethoprim/sulfamethoxazole (Septra), tetracycline, methoxsalen (8-methoxypsoralen, 8-MOP, Oxsoralen), and Trioxsalen (Trisoralen).

Meperidine (Demerol)
St. John's wort increases a chemical in the brain called serotonin. Meperidine (Demerol) can also increase serotonin in the brain. Taking St. John's wort along with meperidine (Demerol) might cause too much serotonin in the brain and serious side effects including heart problems, shivering, and anxiety.

Nefazodone (Serzone)
Nefazodone (Serzone) can increase a chemical in the brain. This chemical is called serotonin. St. John's wort can also increase serotonin. Taking St. John's wort with nefazodone (Serzone) might cause there to be too much serotonin. This could lead to serious side effects including heart problems, shivering, and restlessness.

Nortriptyline (Pamelor)
The body breaks down nortriptyline (Pamelor) to get rid of it. St. John's wort can increase how quickly the body breaks down nortriptyline (Pamelor). This could decrease the effectiveness of nortriptyline (Pamelor).

Paroxetine (Paxil)
Paroxetine (Paxil) increases a chemical in the brain. This chemical is called serotonin. St. John's wort also increases serotonin. Taking paroxetine (Paxil) and St. John's wort together might cause there to be too much serotonin. This could lead to serious side effects including heart problems, shivering, and weakness.

Pentazocine (Talwin)
St. John's wort increases a brain chemical called serotonin. Pentazocine (Talwin) also increases serotonin. Taking St. John's wort along with pentazocine (Talwin) might increase serotonin too much. This could cause serious side effects including heart problems, shivering, and anxiety. Do not take St. John's wort if you are taking pentazocine (Talwin).

Procainamide
St. John's wort extract might increase how much procainamide the body absorbs. This could increase the effects and side effects of procainamide. But the significance of this potential interaction is not known.

Reserpine
St. John's wort can decrease the effects of reserpine.

Sedative medications (Barbiturates)
Medications that cause sleepiness and drowsiness are called sedatives. St. John's wort might decrease the effectiveness of sedative medications. It is not clear why this interaction occurs.

Sertraline (Zoloft)
Sertraline (Zoloft) can increase a chemical in the brain. This chemical is called serotonin. St. John's wort also increases serotonin. This can cause there to be too much serotonin in the brain. This could lead to serious side effects including heart problems, shivering, and irritability.

Simvastatin (Zocor)
The body breaks down simvastatin (Zocor) to get rid of it. St. John's wort increases how quickly the body breaks down simvastatin (Zocor). This can cause simvastatin (Zocor) to be less effective.

Tramadol (Ultram)
Tramadol (Ultram) can affect a chemical in the brain called serotonin. St. John's wort can also affect serotonin. Taking St. John's wort along with tramadol (Ultram) might cause too much serotonin in the brain and side effects including confusion, shivering, stiff muscles, and other side effects.

Minor

Be watchful with this combination.

Methylphenidate (Concerta, Daytrana, Metadate, Ritalin)
Taking St. John's wort along with methylphenidate might decrease how well methylphenidate works for controlling symptoms of attention deficit-hyperactivity disorder (ADHD).

Theophylline
The body breaks down theophylline to get rid of it. St. John's wort might increase how quickly the body gets rid of theophylline. Taking St. John's wort along with theophylline might decrease the effectiveness of theophylline. But it is not clear if this interaction is a big concern.

Are there interactions with herbs and supplements?

Return to top
There are no known interactions with herbs and supplements.

Are there interactions with foods?

Return to top
There are no known interactions with foods.

What dose is used?

Return to top
The following doses have been studied in scientific research:

BY MOUTH:
  • For mild to moderate depression:
    • In most studies, St. John’s wort extract was standardized to 0.3% hypericin content and used at doses of 300 mg three times daily.
    • Some studies have used St. John’s wort extract standardized to 0.2% hypericin at doses of 250 mg twice daily.
    • St. John’s wort extract standardized to 5% hyperforin has been used at doses of 300 mg three times daily.
    • o For children under 12 years of age with depression, St. John’s wort extract standardized to 0.3% hypericin has been used at doses of 300 mg daily.
  • For premenstrual syndrome (PMS): St. John’s wort extract standardized to 0.3% hypericin dosed at 300 mg once daily.
  • For body symptoms associated with depression: 300 mg three times daily of the standardized hypericin extract has been used.
  • For somatization disorder: a specific extract (LI 160, Lichtwer Pharma) 600 mg/day has been used.
Do not suddenly stop taking St. John’s wort. This might cause unpleasant side effects. If you decide to stop taking St. John’s wort, reduce the dose slowly over time.

Other names

Return to top
Amber, Amber Touch-and-Heal, Barbe de Saint-Jean, Chasse-diable, Demon Chaser, Fuga Daemonum, Goatweed, Hardhay, Herbe à la Brûlure, Herbe à Mille Trous, Herbe Aux Fées, Herbe Aux Mille Vertus, Herbe Aux Piqûres, Herbe de Saint Éloi, Herbe de la Saint-Jean, Herbe du Charpentier, Herbe Percée, Hierba de San Juan, Hypereikon, Hyperici Herba, Hypericum perforatum, Klamath Weed, Millepertuis, Millepertuis Perforé, Rosin Rose, Saynt Johannes Wort, SJW, Tipton Weed.

Methodology

Return to top
To learn more about how this article was written, please see the Natural Medicines Comprehensive Database methodology.methodology (http://www.nlm.nih.gov/medlineplus/druginfo/natural/methodology.html).

References

Return to top
To see all references for the St. John's wort page, please go to http://www.nlm.nih.gov/medlineplus/druginfo/natural/329.html.

  1. Halama P. Efficacy of the hypericum extract LI160 in the treatment of 50 patients of a psychiatrist [Wirksamkeit des Johanniskrautextraktes LI 160
  2. Schmidt U, Harrer G, Kuhn U, and Biller A. [Equivalence comparison of the St. John's wort extract lohyp-57 versus fluoxetine HCL]. Zeitschrift fur Phytotherapie 1999;20:89-90.
  3. Schmidt U, Harrer G, Biller A, and Schmidt S. A long-term change-over study with the St. John's wort extract lohyp-57. An observational study of 95 patients with mild and moderate depression. Nervenheilkunde 1999;18:106-109.
  4. Schmidt U, Schenk N, Schwarz I, and et al. Zur Therapie depressiver Verstimmungen. Psycho 1989;15:665-671.
  5. Schlich D, Braukmann F, and Schenk N. Behandlung depressiver zustandsbilder mit hypericum. Psycho 1987;13:440-447.
  6. Quandt J, Schmidt U, and Schenk N. Ambulante behandlung leichter und mittelschwerer depressiver verstiimmungen. Der Allgemeinarzt 1993;2:97-102.
  7. Osterheider M, Schmidtke A, and Beckman H. Behandlung depressiver syndrome mit hypericum (johanniskraut)--eine placebokontrollierte doppelblindstudie. Fortschr.Neurol.Psychiat. 1992;60:210-211.
  8. Kugler J, Schmidt A, Groll S, and et al. Untersuchungen bei Patienten mit depressiven Zustanden im Vergleich zu Bromazepam und Placebo. Ztschr Allgemeinmed 1990;66 (suppl):13-20.
  9. Harrer G, Schmidt U, and Kuhn U. Depressionsbehandlung mit einem hypericum-extrakt. Therapiewoche Neurol Psych 1991;5:710-716.
  10. Randlov C, Thomsen C, Winther K, and et al. Effects of hypericum in mild to moderately depressed outpatients - a placebo-controlled clinical trial [abstract]. Altern Ther Health Med 2001;7:108.
  1. Panijel M. [Treatment of moderately severe anxiety states]. Therapiewoche 1985;35:4659-4668.
  2. Laakmann G, Dienel A, and Kieser M. Clinical significance of hyperforin for the efficacy of Hypericum extracts on depressive disorders of different severities. Phytomedicine 1998;5:435-442.
  3. Abul-Ezz SR, Barone GW Gurley BJ et al. Effect of herbal supplements on cyclosporine blood levels and associated acute rejection. Am Soc of Nephrol Ann Mtg, Toronto, CAN 2000;1.
  4. Turton-Weeks, SM, Barone GW, Gurley BJ, and et al. St. John's wort: a hidden risk for transplant patients. Prog Transplant 2001;11:116-120.
  5. Chatterjee SS, Bhattacharya SK, Singer A, and et al. Hyperforin inhibits synaptosomal uptake of neurotransmitters in vitro and shows antidepressant activity in vivo. Pharmazie 1998;53:9.
  6. Ondrizek RR, Chan PJ, Patton WC, and et al. Inhibition of human sperm motility by specific herbs used in alternative medicine. J Assisted Reproduct Genet 1999;16:87-91.
  7. Schrader E, Meier B, and Brattstrom A. Hypericum treatment of mild-moderate depression in a placebo-controlled study. A prospective, double-blind, randomized, placebo-controlled, multicentre study. Human Psychopharm 1998;13:163-169.
  8. Laird RD and Webb M. Psychotic episode during use of St John's wort. J Herbal Pharmacother 2001;1:81-87.
  9. Schakau D, Hiller K, Schultz-Zehden W, and et al. Risk/benefit profile of St.John's wort extract: STEI 300 in 2404 patients with various degrees of psychiatric disturbance. Psychopharmakotherapie 1996;3:116-122.
  10. Woelk H, Burkard G, and Grunwald J. Nutzen und Risikobewertung des Hypericum-extraktes LI 160 auf der Basis einer Drug-Monitoring-Studie mit 3250 patienten. Nervenheilkunde 1993;12:308-313.
  11. Bachmann LM. Hypericum (St. John's Wort) is just as effective as low dose imipramine. Schweizerische Rundschau fur Medizin Praxis 2000;89:597.
  12. Bernd A, Ramirez-Bosca A, Kippenberger S, and et al. Phototoxic effects of Hypericum extract in cultures of human keratinocytes compared with those of psoralen. Photochem Photobiol 1999;2:218-221.
  13. Cott JM. Herb-drug interactions. CNS Spectrums: The International Journal of Neuropsychiatric Medicine 2001;6:827-832.
  14. Bray BJ, Perry NB, Menkes DB, and et al. St. John's wort extract induces CYP3A and CYP2E1 in the Swiss webster mouse. Toxicol Sci 2002;66:27-33.
  15. Ditzler K and Schatton W. Johanniskraut bei leichten bis mittelschweren Depressionen-Ergebnisse einer plazebo-kontrollierten Doppelblindstudie. Heilkunst 1992;104:263-270.
  16. Hänsgen, D, Vesper J, and Ploch M. Multizentrische Dopple-blinstudie zur antidepressiven Wirksamkeit des Hypercum Extraktes LI 160. Nervenheilkunde 1993;10:285-289.
  17. Chavez ML and Chavez PI. Saint John's wort. Hospital Pharm 1997;32:1621-1632.
  18. Zeller K. A convincing safety profile of St. John's Wort extract (Laif® 600) showed in a large post marketing surveillance [abstract]. Phytomedicine 2000;7(suppl 11):107.
  19. Muller, B. Johanniskraut in der Therapie depressiver Verstimmungen. Med.Welt. 1999;50:307-310.
  20. Grube, B. Grünwald J. Walper A. Hopfenmüller W. Johanniskraut bei leichten tempora ¨ren Verstimmungen. Anwendungsbeobachtung belegt Behandlungserfolg. Naturamed 1996;111:21-27.
  21. Ditzler K, Gessner B, Schatton WFH, and et al. Clinical trial on Neuropas versus placebo in patients with mild to moderate depressive symptoms: a placebo-controlled, randomised double-blind study. Comp Ther Med 1994;2:5-13.
  22. Halama P. Wirksamkeit des Johanniskrautextraktes LI 160 bei depressiver Verstimmung. Nervenheilkunde 1991;10:250-253.
  23. Gewertz N, Ereshefsky B, Lam YW, and et al. Determination of differential effects of St. John's wort on the CYPIA2 and NAT2 metabolic pathways using caffeine probe technology. Abstracts from the 39th Annual Meeting of the New Clinical Drug Evaluation Unit 1999;131.
  24. Panossian AG, Gabrielian E, Manvelian V, and et al. Immunosuppressive effects of hypericin on stimulated human leukocytes: inhibition of the arachidonic acid release, leukotriene B
  25. Bombardelli E and Morazzoni P. Hypericum perforatum. Fitoterapia 1995;66:43-68.
  26. Colker, Kalman, Torina, and et al. Effects of citrus aurantium extract, caffeine, and st. John's wort on body fat loss, lipid levels, and mood states in overweight healthy adults. Current Therapeutic Research, Clinical & Experimental 1999;60:145-153.
  27. Wood S, Huffman J, Weber N, and et al. Antiviral activity of naturally occurring anthraquinones and anthraquinone derivatives. Planta Med 1990;56:651-652.
  28. Werth W. Psychotonin M versus imipramin in der chirugie. Der Kassenarzt 1989;15:64-68.
  29. Demisch L, Holzl J, Gollnik B, and et al. Identification of selective MAO-type-A inhibitors in Hypericum perforatum L. (Hyperforat). Pharmacopsychiat. 1989;22:194.
  30. Sommer H and Harrer G. Plazebo-kontrollierte studie zur wirksamkeit des hypericum-praparates LI 160 bei 105 patienten mit depression. Nervenheikunde 1993;12:277.
  31. Hubner WD, Lande S, and Podzuweit H. Behandlung larvierter Depressionen mit Johanniskraut. Nervenheilkunde 1993;12:278-280.
  32. Schmidt U, Harrer U, Kuhn W, and et al. Interaction of Hypericum extract with alcohol. Placebo controlled study with 32 volunteers. Nervenheilkunde 1993;12:314-319.
  33. Sultana D, Peindl KS Wisner KL. Rash associated with St. John's wort treatment in premenstrual dysphoric disorder. Arch Women Ment Health 2000;3:99-101.
  34. Poginsky B, Westendorf J, Prosenc N, and et al. Johanniskraut (Hypercum perforatum L.). Genotoxizität bedingt durch den Quercetingehalt. Deutsche Apotheker Zeitung 1988;128:1364-1366.
  35. Leuschner G. Preclinical toxicology profile of Hypericum extract LI 160. Phytomedicine 1996;supplement 1:104.
  36. Schempp, M., Hezel, S., and Simon, C. [Topical treatment of Atopic dermatitis with Hypericum cream. A randomised, placebo-controlled, double-blind half-side comparison study]. Hautarzt 2003;54:248-253.
  37. Warnecke G. Beeinflussung klimakterischer depressionen. Z.Allg.Med. 1986;62:1111-1113.
  38. Vorbach EU, Hubner W-D, and Arnoldt K. Wirksamkeit und Vertraglichkeit der Hypericum-Extraktes LI 160 im Verleich mit Imipramin. Nervenheilkunde 1993;12:290-296.
  39. Halama P. Efficacy of the hypericum extract LI160 in the treatment of 50 patients of a psychiatrist [Wirksamkeit des Johanniskrautextraktes LI 160 bei depressiver Verstimmung Nervenheilkunde]. Nervenheilkunde 1991;10:305-307.
  40. Shelton R and Crits-Christoph P. St. John's wort and major depression. JAMA 2001;286:42-45.
  41. Meltzer-Brody SE. St. John's wort: clinical status in psychiatry. CNS Spectrums: The International Journal of Neuropsychiatric Medicine 2001;6:835-847.
  42. Williams, J. W., Jr., Mulrow, C. D., Chiquette, E., Noel, P. H., Aguilar, C., and Cornell, J. A systematic review of newer pharmacotherapies for depression in adults: evidence report summary. Ann Intern.Med 5-2-2000;132:743-756.
  43. Ernst E. St. John's Wort, an anti-depressant? A systematic, criteria-based review. Phytomed 1995;2:67-71.
  44. Woelk H, Beneke M, Gebert I, Rappard F, and Rechziegler H. Hypericum extract Ze 117:an open long-term study in patients with milk-moderate depression. Phytomedicine 2000;Suppl 2:109:P-115.
  45. Sephermanesh, M. Johanniskrautextrakt in derärztlichen Praxis. Allg.Med.Z 1999;75:170-173.
  46. Rychlik, R., Siedentop, H., von, den Driesch, V, and Kasper, S. [St. John's wort extract WS 5572 in minor to moderately severe depression. Effectiveness and tolerance of 600 and 1200 mg active ingredient daily]. Fortschr Med Orig. 11-29-2001;119(3-4):119-128.
  47. Meier, B. Liske E. Rosinus V. Wirksamkeit und Verträglichkeit eines standardisierten Johanniskraut- Vollextraktes (Ze117) bei Patienten mit depressiver Symptomatik unterschiedlicher Schweregrade-eine An- wendungsbeobachtung. Forsch.Komplementa ¨rmed. 1997;4:87-93.
  48. Lemmer, W. von den Driesch V. Klieser E. Johanniskraut-Spezialextrakt WS 5572 bei leichter bis mittelschwerer Depression. MMW Fortschr.Med. 1999;117:143-154.
  49. Kalb, R. Arnoldt K. H. Kleemann A. Langzeitbe- handlung mit Johanniskrautextrakt LI 160. Der Allgemei- narzt 1999;21:1726-1728.
  50. Holsboer-Trachsler, E. and Vanoni, C. [Clinical efficacy and tolerance of the hypericum special extract LI 160 in depressive disorders--a drug monitoring study]. Praxis.(Bern.1994.) 9-9-1999;88:1475-1480.
  51. Albrecht, M. Hübner W. D. Podzuweit H. Schmidt U. Johanniskraut-Extrakt zur Behandlung der Depres- sion. Therapiebegleitende Anwendungsbeobachtung mit Jarsins Dragees.Der Kassenarzt 1994;41:45-54.
  52. König CD. Hypericum perforatum L. (gemeines Johanniskraut) als Therapeutikum bei depressiven Verstimmungszuständen - eine Alternative zu synthetischen Arzneimitteln. University of Basel Thesis, 1993 (not available for review, cited in: Linde K, Mulrow CD.St John's wort for depression.The Cochrane Library, Oxford, Update Software, 2002[1])
  53. Kniebel R and Burchard J. Zur therapie depressiver verstimmungen in der praxis. Z.Allg.Med. 1988;64:689-696.
  54. Steger W. Depressive Verstimmungen. Z.Allg.Med. 1985;61:914-918.
  55. Harrer G and Sommer H. Treatment of mild /moderate depressions with Hypericum. Phytomed 1994;1:3-8.
  56. Hänsgen KD and Vesper J. Antidepressive Wirksamkeit eines hochdosierten Hypericum-Extraktes. Muench med Wschr 1996;138:29-33.
  57. Lecrubier Y. Clinical significance of hyperforin for the efficacy of Hypericum extracts on depressive disorders of different severities. Eur Neuropsychopharmacol 2001;11:105-106.
  58. Laakmann, G., Schule, C., Baghai, T., and Kieser, M. St. John's wort in mild to moderate depression: the relevance of hyperforin for the clinical efficacy. Pharmacopsychiatry 1998;31 Suppl 1:54-59.
  59. Schmidt, U. and Sommer, H. [St. John's wort extract in the ambulatory therapy of depression. Attention and reaction ability are preserved]. Fortschr.Med 7-10-1993;111:339-342.
  60. Gurley, B. J., Gardner, S. F., Hubbard, M. A., Williams, D. K., Gentry, W. B., Cui, Y., and Ang, C. Y. Cytochrome P450 phenotypic ratios for predicting herb-drug interactions in humans. Clin.Pharmacol.Ther. 2002;72:276-287.
  61. Sharpley AL, McGavin Cl, Whale R, and Cowen PJ. Hypericum perforatum (St. John's Wort) and depression?: Changes in sleep architecture in normal volunteers. XXIst Collegium Internationale Neuro-psychopharmacologicum, Glasgow, Scotland 12-16th July, 1998.
  62. Hennessy, M., Kelleher, D., Spiers, J. P., Barry, M., Kavanagh, P., Back, D., Mulcahy, F., and Feely, J. St Johns wort increases expression of P-glycoprotein: implications for drug interactions. Br J Clin Pharmacol 2002;53:75-82.
  63. Bergmann R, Nuessner J, and Demling J. Treatment of mild to moderate depressions: a comparison between hypericum perforatum and amitryptiline. Neurologie/Psychiatrie 1993;7:235-240.
  64. Nelson JC. Tricyclics and tetracyclics. In: Sadock BJ and Sadock. Comprehensive Textbook of Psychiatry. Philadelphia, PA: Lippincott Williams & Wilkins;2000.
  65. Maisenbacher HJ and Kuhn U. The therapy of depressions in practice: Results of a post-marketing surveillance study with Herba Hyperici. Natura Medica 1992;7:394-399.
  66. Reh C, Laux P, and Schenk N. Hypericum-extrakt bei depressionen eine wirksame alternative. Therapiewoche 1992;42:1576-1581.
  67. Haring B, Hauns B, Hermann C, and et al. A double-blind, placebo-controlled pilot study of LI 160 in combination with chemotherapy in patients with solid tumors. Abstracts of the 2nd International Congress on Phytomedicine 1996;SL-88.
  68. Hoffmann J and Kuhl ED. Therapie von depressiven Zustanden mit Hypericin. Z Allgemeinmed 1979;55:776-782.
  69. Lehrl S, Willemsen A, Papp R, and et al. Ergebnisse von Messungen der kognitiven Leistungsfahigkeit bei Patienten unter der Therapie mit Johanniskraut-Extrakt. Nervenheilkunde 1993;12:281-289.
  70. Hubner, W. D., Lande, S., and Podzuweit, H. Hypericum treatment of mild depressions with somatic symptoms. J.Geriatr.Psychiatry Neurol. 1994;7 Suppl 1:S12-S14.
  71. Philipp, M., Kohnen, R., and Hiller, K. O. Hypericum extract versus imipramine or placebo in patients with moderate depression: randomised multicentre study of treatment for eight weeks. BMJ 12-11-1999;319:1534-1538.
  72. Mills, E., Montori, V. M., Wu, P., Gallicano, K., Clarke, M., and Guyatt, G. Interaction of St John's wort with conventional drugs: systematic review of clinical trials. BMJ 7-3-2004;329:27-30.
  73. Volz, H. P. [Somatoform disorders--what must the general practitioner know?]. MMW.Fortschr.Med 8-19-2004;146(33-34):27-8, 30.
  74. Witte, B., Harrer, G., Kaptan, T., Podzuweit, H., and Schmidt, U. [Treatment of depressive symptoms with a high concentration hypericum preparation. A multicenter placebo-controlled double-blind study]. Fortschr.Med 10-10-1995;113:404-408.
  75. Harrer G, Hubner WD, and Podzuweit H. Effectiveness and tolerance of the hypericum extract LI 160 compared to maprotiline: a multicenter double blind study. J Geriatr.Psychiatry Neurol. 1994;7:S24-S28.
  76. Harrer G and Sommer H. Therapie leichter/mittelschwerer Depressionen mit Hypericum. Muench med Wschr 1993;135:305-309.
  77. Harrer G, Hubner W-D, and Podzuweit H. Wirksamkeit und Vertraglichkeit des Hypericum-Praparates LI 160 im Vergleich mit Maprotilin. Nervenheilkunde 1993;12:297-301.
  78. Wheatley, D. LI 160, an extract of St. John's wort, versus amitriptyline in mildly to moderately depressed outpatients--a controlled 6-week clinical trial. Pharmacopsychiatry 1997;30 Suppl 2:77-80.
  79. Neary, J. T. and Bu, Y. Hypericum LI 160 inhibits uptake of serotonin and norepinephrine in astrocytes. Brain Res 1-23-1999;816:358-363. View abstract.
  80. Sharpley, A. L., McGavin, C. L., Whale, R., and Cowen, P. J. Antidepressant-like effect of Hypericum perforatum (St John's wort) on the sleep polysomnogram. Psychopharmacology (Berl) 1998;139:286-287. View abstract.
  81. Chatterjee, S. S., Bhattacharya, S. K., Wonnemann, M., Singer, A., and Muller, W. E. Hyperforin as a possible antidepressant component of hypericum extracts. Life Sci 1998;63:499-510. View abstract.
  82. Schellenberg, R., Sauer, S., and Dimpfel, W. Pharmacodynamic effects of two different hypericum extracts in healthy volunteers measured by quantitative EEG. Pharmacopsychiatry 1998;31 Suppl 1:44-53. View abstract.
  83. Biber, A., Fischer, H., Romer, A., and Chatterjee, S. S. Oral bioavailability of hyperforin from hypericum extracts in rats and human volunteers. Pharmacopsychiatry 1998;31 Suppl 1:36-43. View abstract.
  84. Bhattacharya, S. K., Chakrabarti, A., and Chatterjee, S. S. Activity profiles of two hyperforin-containing hypericum extracts in behavioral models. Pharmacopsychiatry 1998;31 Suppl 1:22-29. View abstract.
  85. Raffa, R. B. Screen of receptor and uptake-site activity of hypericin component of St. John's wort reveals sigma receptor binding. Life Sci 1998;62:L265-L270. View abstract.
  86. Nahrstedt, A. and Butterweck, V. Biologically active and other chemical constituents of the herb of Hypericum perforatum L. Pharmacopsychiatry 1997;30 Suppl 2:129-134. View abstract.
  87. Butterweck, V., Wall, A., Lieflander-Wulf, U., Winterhoff, H., and Nahrstedt, A. Effects of the total extract and fractions of Hypericum perforatum in animal assays for antidepressant activity. Pharmacopsychiatry 1997;30 Suppl 2:117-124. View abstract.
  88. Teufel-Mayer, R. and Gleitz, J. Effects of long-term administration of hypericum extracts on the affinity and density of the central serotonergic 5-HT1 A and 5-HT2 A receptors. Pharmacopsychiatry 1997;30 Suppl 2:113-116. View abstract.
  89. Cott, J. M. In vitro receptor binding and enzyme inhibition by Hypericum perforatum extract. Pharmacopsychiatry 1997;30 Suppl 2:108-112. View abstract.
  90. Müller WE, Rolli, M., Schafer, C., and Hafner, U. Effects of hypericum extract (LI 160) in biochemical models of antidepressant activity. Pharmacopsychiatry 1997;30 Suppl 2:102-107. View abstract.
  91. Kerb, R., Brockmoller, J., Staffeldt, B., Ploch, M., and Roots, I. Single-dose and steady-state pharmacokinetics of hypericin and pseudohypericin. Antimicrob.Agents Chemother. 1996;40:2087-2093. View abstract.
  92. Cohen, P. A., Hudson, J. B., and Towers, G. H. Antiviral activities of anthraquinones, bianthrones and hypericin derivatives from lichens. Experientia 2-15-1996;52:180-183. View abstract.
  93. Schmidt, U. and Sommer, H. [St. John's wort extract in the ambulatory therapy of depression. Attention and reaction ability are preserved]. Fortschr.Med 7-10-1993;111:339-342. View abstract.
  94. Hudson, J. B., Graham, E. A., and Towers, G. H. Antiviral assays on phytochemicals: the influence of reaction parameters. Planta Med. 1994;60:329-332. View abstract.
  95. Thiele, B., Brink, I., and Ploch, M. Modulation of cytokine expression by hypericum extract. J Geriatr.Psychiatry Neurol. 1994;7 Suppl 1:S60-S62. View abstract.
  96. Harrer, G. and Schulz, V. Clinical investigation of the antidepressant effectiveness of hypericum. J Geriatr.Psychiatry Neurol. 1994;7 Suppl 1:S6-S8. View abstract.
  97. Bladt, S. and Wagner, H. Inhibition of MAO by fractions and constituents of hypericum extract. J Geriatr.Psychiatry Neurol. 1994;7 Suppl 1:S57-S59. View abstract.
  98. Thiede, H. M. and Walper, A. Inhibition of MAO and COMT by hypericum extracts and hypericin. J Geriatr.Psychiatry Neurol. 1994;7 Suppl 1:S54-S56. View abstract.
  99. Staffeldt, B., Kerb, R., Brockmoller, J., Ploch, M., and Roots, I. Pharmacokinetics of hypericin and pseudohypericin after oral intake of the hypericum perforatum extract LI 160 in healthy volunteers. J Geriatr.Psychiatry Neurol. 1994;7 Suppl 1:S47-S53. View abstract.
  100. Johnson, D., Ksciuk, H., Woelk, H., Sauerwein-Giese, E., and Frauendorf, A. Effects of hypericum extract LI 160 compared with maprotiline on resting EEG and evoked potentials in 24 volunteers. J Geriatr.Psychiatry Neurol. 1994;7 Suppl 1:S44-S46. View abstract.
  101. Schulz, H. and Jobert, M. Effects of hypericum extract on the sleep EEG in older volunteers. J Geriatr.Psychiatry Neurol. 1994;7 Suppl 1:S39-S43. View abstract.
  102. Woelk, H., Burkard, G., and Grunwald, J. Benefits and risks of the hypericum extract LI 160: drug monitoring study with 3250 patients. J Geriatr.Psychiatry Neurol. 1994;7 Suppl 1:S34-S38. View abstract.
  103. Martinez, B., Kasper, S., Ruhrmann, S., and Moller, H. J. Hypericum in the treatment of seasonal affective disorders. J Geriatr.Psychiatry Neurol. 1994;7 Suppl 1:S29-S33. View abstract.
  104. Harrer, G., Hubner, W. D., and Podzuweit, H. Effectiveness and tolerance of the hypericum extract LI 160 compared to maprotiline: a multicenter double-blind study. J.Geriatr.Psychiatry Neurol. 1994;7 Suppl 1:S24-S28. View abstract.
  105. Couldwell, W. T., Gopalakrishna, R., Hinton, D. R., He, S., Weiss, M. H., Law, R. E., Apuzzo, M. L., and Law, R. E. Hypericin: a potential antiglioma therapy. Neurosurgery 1994;35:705-710. View abstract.
  106. Witte, B., Harrer, G., Kaptan, T., Podzuweit, H., and Schmidt, U. [Treatment of depressive symptoms with a high concentration hypericum preparation. A multicenter placebo-controlled double-blind study]. Fortschr.Med 10-10-1995;113:404-408. View abstract.
  107. Araya, O. S. and Ford, E. J. An investigation of the type of photosensitization caused by the ingestion of St John's Wort (Hypericum perforatum) by calves. J Comp Pathol 1981;91:135-141. View abstract.
  108. Suzuki, O., Katsumata, Y., Oya, M., Bladt, S., and Wagner, H. Inhibition of monoamine oxidase by hypericin. Planta Med 1984;50:272-274. View abstract.
  109. Meruelo, D., Lavie, G., and Lavie, D. Therapeutic agents with dramatic antiretroviral activity and little toxicity at effective doses: aromatic polycyclic diones hypericin and pseudohypericin. Proc.Natl.Acad.Sci U.S.A 1988;85:5230-5234. View abstract.
  110. Lavie, G., Valentine, F., Levin, B., Mazur, Y., Gallo, G., Lavie, D., Weiner, D., and Meruelo, D. Studies of the mechanisms of action of the antiretroviral agents hypericin and pseudohypericin. Proc Natl.Acad.Sci U.S.A 1989;86:5963-5967. View abstract.
  111. Najafizadeh, P., Hashemian, F., Mansouri, P., Farshi, S., Surmaghi, M. S., and Chalangari, R. The evaluation of the clinical effect of topical St Johns wort (Hypericum perforatum L.) in plaque type psoriasis vulgaris: a pilot study. Australas.J.Dermatol. 2012;53:131-135. View abstract.
  112. Meinke, M. C., Schanzer, S., Haag, S. F., Casetti, F., Muller, M. L., Wolfle, U., Kleemann, A., Lademann, J., and Schempp, C. M. In vivo photoprotective and anti-inflammatory effect of hyperforin is associated with high antioxidant activity in vitro and ex vivo. Eur.J.Pharm.Biopharm. 2012;81:346-350. View abstract.
  113. Okpanyi, S. N., Lidzba, H., Scholl, B. C., and Miltenburger, H. G. [Genotoxicity of a standardized Hypericum extract]. Arzneimittelforschung. 1990;40:851-855. View abstract.
  114. Clewell, A., Barnes, M., Endres, J. R., Ahmed, M., and Ghambeer, D. K. Efficacy and tolerability assessment of a topical formulation containing copper sulfate and hypericum perforatum on patients with herpes skin lesions: a comparative, randomized controlled trial. J.Drugs Dermatol. 2012;11:209-215. View abstract.
  115. Van Strater, A. C. and Bogers, J. P. Interaction of St John's wort (Hypericum perforatum) with clozapine. Int.Clin.Psychopharmacol. 2012;27:121-124. View abstract.
  116. Singer, A., Schmidt, M., Hauke, W., and Stade, K. Duration of response after treatment of mild to moderate depression with Hypericum extract STW 3-VI, citalopram and placebo: a reanalysis of data from a controlled clinical trial. Phytomedicine. 6-15-2011;18(8-9):739-742. View abstract.
  117. Engelhardt, V., Kiesslich, T., Berlanda, J., Hofbauer, S., Krammer, B., and Plaetzer, K. Lipophilic rather than hydrophilic photosensitizers show strong adherence to standard cell culture microplates under cell-free conditions. J.Photochem.Photobiol.B 6-2-2011;103:222-229. View abstract.
  118. Couldwell, W. T., Surnock, A. A., Tobia, A. J., Cabana, B. E., Stillerman, C. B., Forsyth, P. A., Appley, A. J., Spence, A. M., Hinton, D. R., and Chen, T. C. A phase 1/2 study of orally administered synthetic hypericin for treatment of recurrent malignant gliomas. Cancer 11-1-2011;117:4905-4915. View abstract.
  119. Ghazanfarpour, M., Kaviani, M., Asadi, N., Ghaffarpasand, F., Ziyadlou, S., Tabatabaee, H. R., and Dehghankhalili, M. Hypericum perforatum for the treatment of premenstrual syndrome. Int.J.Gynaecol.Obstet. 2011;113:84-85. View abstract.
  120. Bitran, S., Farabaugh, A. H., Ameral, V. E., LaRocca, R. A., Clain, A. J., Fava, M., and Mischoulon, D. Do early changes in the HAM-D-17 anxiety/somatization factor items affect the treatment outcome among depressed outpatients? Comparison of two controlled trials of St John's wort (Hypericum perforatum) versus a SSRI. Int.Clin.Psychopharmacol. 2011;26:206-212. View abstract.
  121. Rook, A. H., Wood, G. S., Duvic, M., Vonderheid, E. C., Tobia, A., and Cabana, B. A phase II placebo-controlled study of photodynamic therapy with topical hypericin and visible light irradiation in the treatment of cutaneous T-cell lymphoma and psoriasis. J.Am.Acad.Dermatol. 2010;63:984-990. View abstract.
  122. Bancirova, M. and Lasovsky, J. The photodynamic effect: the comparison of chemiexcitation by luminol and phthalhydrazide. Luminescence. 2011;26:410-415. View abstract.
  123. Kasper, S., Caraci, F., Forti, B., Drago, F., and Aguglia, E. Efficacy and tolerability of Hypericum extract for the treatment of mild to moderate depression. Eur.Neuropsychopharmacol. 2010;20:747-765. View abstract.
  124. Berlanda, J., Kiesslich, T., Engelhardt, V., Krammer, B., and Plaetzer, K. Comparative in vitro study on the characteristics of different photosensitizers employed in PDT. J.Photochem.Photobiol.B 9-2-2010;100:173-180. View abstract.
  125. Kasper, S., Gastpar, M., Moller, H. J., Muller, W. E., Volz, H. P., Dienel, A., and Kieser, M. Better tolerability of St. John's wort extract WS 5570 compared to treatment with SSRIs: a reanalysis of data from controlled clinical trials in acute major depression. Int.Clin.Psychopharmacol. 2010;25:204-213. View abstract.
  126. Boiy, A., de Witte, P. A., and Roelandts, R. Topical treatment of disseminated superficial actinic porokeratosis with hypericin-photodynamic therapy: a case report. Photodiagnosis.Photodyn.Ther. 2010;7:123-125. View abstract.
  127. Melzer, J., Brignoli, R., Keck, M. E., and Saller, R. A hypericum extract in the treatment of depressive symptoms in outpatients: an open study. Forsch.Komplementmed. 2010;17:7-14. View abstract.
  128. Canning, S., Waterman, M., Orsi, N., Ayres, J., Simpson, N., and Dye, L. The efficacy of Hypericum perforatum (St John's wort) for the treatment of premenstrual syndrome: a randomized, double-blind, placebo-controlled trial. CNS.Drugs 2010;24:207-225. View abstract.
  129. Leuner, K., Heiser, J. H., Derksen, S., Mladenov, M. I., Fehske, C. J., Schubert, R., Gollasch, M., Schneider, G., Harteneck, C., Chatterjee, S. S., and Muller, W. E. Simple 2,4-diacylphloroglucinols as classic transient receptor potential-6 activators--identification of a novel pharmacophore. Mol.Pharmacol. 2010;77:368-377. View abstract.
  130. Brattstrom, A. Long-term effects of St. John's wort (Hypericum perforatum) treatment: a 1-year safety study in mild to moderate depression. Phytomedicine. 2009;16:277-283. View abstract.
  131. Tardivo, J. P. and Baptista, M. S. Treatment of osteomyelitis in the feet of diabetic patients by photodynamic antimicrobial chemotherapy. Photomed.Laser Surg. 2009;27:145-150. View abstract.
  132. Al-Akoum, M., Maunsell, E., Verreault, R., Provencher, L., Otis, H., and Dodin, S. Effects of Hypericum perforatum (St. John's wort) on hot flashes and quality of life in perimenopausal women: a randomized pilot trial. Menopause. 2009;16:307-314. View abstract.
  133. Ott, M., Fricker, G., and Bauer, B. Pregnane X receptor (PXR) regulates P-glycoprotein at the blood-brain barrier: functional similarities between pig and human PXR. J.Pharmacol.Exp.Ther. 2009;329:141-149. View abstract.
  134. Rahimi, R., Nikfar, S., and Abdollahi, M. Efficacy and tolerability of Hypericum perforatum in major depressive disorder in comparison with selective serotonin reuptake inhibitors: a meta-analysis. Prog.Neuropsychopharmacol.Biol.Psychiatry 2-1-2009;33:118-127. View abstract.
  135. Linde, K., Berner, M. M., and Kriston, L. St John's wort for major depression. Cochrane.Database.Syst.Rev. 2008;:CD000448. View abstract.
  136. Zaher, M., Akrout, I., Mirshahi, M., Kolb, J. P., and Billard, C. Noxa upregulation is associated with apoptosis of chronic lymphocytic leukemia cells induced by hyperforin but not flavopiridol. Leukemia 2009;23:594-596. View abstract.
  137. Mueller, S. C., Majcher-Peszynska, J., Mundkowski, R. G., Uehleke, B., Klammt, S., Sievers, H., Lehnfeld, R., Frank, B., Thurow, K., Kundt, G., and Drewelow, B. No clinically relevant CYP3A induction after St. John's wort with low hyperforin content in healthy volunteers. Eur.J.Clin.Pharmacol. 2009;65:81-87. View abstract.
  138. Kasper, S., Volz, H. P., Moller, H. J., Dienel, A., and Kieser, M. Continuation and long-term maintenance treatment with Hypericum extract WS 5570 after recovery from an acute episode of moderate depression--a double-blind, randomized, placebo controlled long-term trial. Eur.Neuropsychopharmacol. 2008;18:803-813. View abstract.
  139. Carvalho, L. A., Gorenstein, C., Moreno, R., Pariante, C., and Markus, R. P. Effect of antidepressants on melatonin metabolite in depressed patients. J.Psychopharmacol. 2009;23:315-321. View abstract.
  140. Zhou, S. F. and Lai, X. An update on clinical drug interactions with the herbal antidepressant St. John's wort. Curr.Drug Metab 2008;9:394-409. View abstract.
  141. Andreescu, C., Mulsant, B. H., and Emanuel, J. E. Complementary and alternative medicine in the treatment of bipolar disorder--a review of the evidence. J.Affect.Disord. 2008;110(1-2):16-26. View abstract.
  142. Bent, S. Herbal medicine in the United States: review of efficacy, safety, and regulation: grand rounds at University of California, San Francisco Medical Center. J.Gen.Intern.Med. 2008;23:854-859. View abstract.
  143. Etogo-Asse, F., Boemer, F., Sempoux, C., and Geubel, A. Acute hepatitis with prolonged cholestasis and disappearance of interlobular bile ducts following tibolone and Hypericum perforatum (St. John's wort). Case of drug interaction? Acta Gastroenterol.Belg. 2008;71:36-38. View abstract.
  144. Nowack, R. Review article: cytochrome P450 enzyme, and transport protein mediated herb-drug interactions in renal transplant patients: grapefruit juice, St John's Wort - and beyond! Nephrology.(Carlton.) 2008;13:337-347. View abstract.
  145. Sardella, A., Lodi, G., Demarosi, F., Tarozzi, M., Canegallo, L., and Carrassi, A. Hypericum perforatum extract in burning mouth syndrome: a randomized placebo-controlled study. J.Oral Pathol.Med. 2008;37:395-401. View abstract.
  146. Papakostas, G. I., Crawford, C. M., Scalia, M. J., and Fava, M. Timing of clinical improvement and symptom resolution in the treatment of major depressive disorder. A replication of findings with the use of a double-blind, placebo-controlled trial of Hypericum perforatum versus fluoxetine. Neuropsychobiology 2007;56(2-3):132-137. View abstract.
  147. Saarto, T. and Wiffen, P. J. Antidepressants for neuropathic pain. Cochrane.Database.Syst.Rev. 2007;:CD005454. View abstract.
  148. Schwarz, U. I., Hanso, H., Oertel, R., Miehlke, S., Kuhlisch, E., Glaeser, H., Hitzl, M., Dresser, G. K., Kim, R. B., and Kirch, W. Induction of intestinal P-glycoprotein by St John's wort reduces the oral bioavailability of talinolol. Clin.Pharmacol.Ther. 2007;81:669-678. View abstract.
  149. Dominguez Jimenez, J. L., Pleguezuelo, Navarro M., Guiote, Malpartida S., Fraga, Rivas E., Montero Alvarez, J. L., and Poyato, Gonzalez A. [Hepatotoxicity associated with Hypericum (St. John's wort)]. Gastroenterol.Hepatol. 2007;30:54-55. View abstract.
  150. Cappuzzo, K. A. Herbal product use in a patient with polypharmacy. Consult Pharm. 2006;21:911-915. View abstract.
  151. Carpenter, S. and Kraus, G. A. Photosensitization is required for inactivation of equine infectious anemia virus by hypericin. Photochem.Photobiol. 1991;53:169-174. View abstract.
  152. Whitten, D. L., Myers, S. P., Hawrelak, J. A., and Wohlmuth, H. The effect of St John's wort extracts on CYP3A: a systematic review of prospective clinical trials. Br.J.Clin.Pharmacol. 2006;62:512-526. View abstract.
  153. Tang, J., Colacino, J. M., Larsen, S. H., and Spitzer, W. Virucidal activity of hypericin against enveloped and non-enveloped DNA and RNA viruses. Antiviral Res 1990;13:313-325. View abstract.
  154. Schinazi, R. F., Chu, C. K., Babu, J. R., Oswald, B. J., Saalmann, V., Cannon, D. L., Eriksson, B. F., and Nasr, M. Anthraquinones as a new class of antiviral agents against human immunodeficiency virus. Antiviral Res 1990;13:265-272. View abstract.
  155. Clement, K., Covertson, C. R., Johnson, M. J., and Dearing, K. St. John's wort and the treatment of mild to moderate depression: a systematic review. Holist.Nurs.Pract. 2006;20:197-203. View abstract.
  156. Moreno, R. A., Teng, C. T., Almeida, K. M., and Tavares, Junior H. Hypericum perforatum versus fluoxetine in the treatment of mild to moderate depression: a randomized double-blind trial in a Brazilian sample. Rev.Bras.Psiquiatr. 2006;28:29-32. View abstract.
  157. Lopez-Bazzocchi, I., Hudson, J. B., and Towers, G. H. Antiviral activity of the photoactive plant pigment hypericin. Photochem.Photobiol. 1991;54:95-98. View abstract.
  158. Gastpar, M., Singer, A., and Zeller, K. Comparative efficacy and safety of a once-daily dosage of hypericum extract STW3-VI and citalopram in patients with moderate depression: a double-blind, randomised, multicentre, placebo-controlled study. Pharmacopsychiatry 2006;39:66-75. View abstract.
  159. Hudson, J. B., Lopez-Bazzocchi, I., and Towers, G. H. Antiviral activities of hypericin. Antiviral Res 1991;15:101-112. View abstract.
  160. Randlov, C., Mehlsen, J., Thomsen, C. F., Hedman, C., von, Fircks H., and Winther, K. The efficacy of St. John's Wort in patients with minor depressive symptoms or dysthymia--a double-blind placebo-controlled study. Phytomedicine. 2006;13:215-221. View abstract.
  161. Lawvere, S. and Mahoney, M. C. St. John's wort. Am.Fam.Physician 12-1-2005;72:2249-2254. View abstract.
  162. Donovan, J. L., DeVane, C. L., Lewis, J. G., Wang, J. S., Ruan, Y., Chavin, K. D., and Markowitz, J. S. Effects of St John's wort (Hypericum perforatum L.) extract on plasma androgen concentrations in healthy men and women: a pilot study. Phytother Res 2005;19:901-906. View abstract.
  163. Demiroglu, Y. Z., Yeter, T. T., Boga, C., Ozdogu, H., Kizilkilic, E., Bal, N., Tuncer, I., and Arslan, H. Bone marrow necrosis: a rare complication of herbal treatment with Hypericum perforatum (St. John's wort). Acta Medica.(Hradec.Kralove) 2005;48:91-94. View abstract.
  164. Krusekopf, S. and Roots, I. St. John's wort and its constituent hyperforin concordantly regulate expression of genes encoding enzymes involved in basic cellular pathways. Pharmacogenet.Genomics 2005;15:817-829. View abstract.
  165. Fava, M., Alpert, J., Nierenberg, A. A., Mischoulon, D., Otto, M. W., Zajecka, J., Murck, H., and Rosenbaum, J. F. A Double-blind, randomized trial of St John's wort, fluoxetine, and placebo in major depressive disorder. J.Clin.Psychopharmacol. 2005;25:441-447. View abstract.
  166. Hansen, R. S., Paulsen, I., and Davies, M. Determinants of amentoflavone interaction at the GABA(A) receptor. Eur.J Pharmacol 9-20-2005;519:199-207. View abstract.
  167. Nanayakkara, P. W., Meijboom, M., and Schouten, J. A. [Suicidal and aggressive thoughts as a result of taking a Hypericum preparation (St. John's wort)]. Ned.Tijdschr.Geneeskd. 6-11-2005;149:1347-1349. View abstract.
  168. Simeon, J., Nixon, M. K., Milin, R., Jovanovic, R., and Walker, S. Open-label pilot study of St. John's wort in adolescent depression. J Child Adolesc.Psychopharmacol. 2005;15:293-301. View abstract.
  169. Traynor, N. J., Beattie, P. E., Ibbotson, S. H., Moseley, H., Ferguson, J., and Woods, J. A. Photogenotoxicity of hypericin in HaCaT keratinocytes: implications for St. John's Wort supplements and high dose UVA-1 therapy. Toxicol.Lett. 9-15-2005;158:220-224. View abstract.
  170. Capasso, R., Borrelli, F., Montanaro, V., Altieri, V., Capasso, F., and Izzo, A. A. Effects of the antidepressant St. John's wort (Hypericum perforatum) on rat and human vas deferens contractility. J Urol. 2005;173:2194-2197. View abstract.
  171. Vitiello, B., Shader, R. I., Parker, C. B., Ritz, L., Harlan, W., Greenblatt, D. J., Gadde, K. M., Krishnan, K. R., and Davidson, J. R. Hyperforin plasma level as a marker of treatment adherence in the National Institutes of Health Hypericum Depression Trial. J Clin.Psychopharmacol. 2005;25:243-249. View abstract.
  172. Gastpar, M., Singer, A., and Zeller, K. Efficacy and tolerability of hypericum extract STW3 in long-term treatment with a once-daily dosage in comparison with sertraline. Pharmacopsychiatry 2005;38:78-86. View abstract.
  173. Linde, K., Berner, M., Egger, M., and Mulrow, C. St John's wort for depression: meta-analysis of randomised controlled trials. Br.J Psychiatry 2005;186:99-107. View abstract.
  174. Hicks, S. M., Walker, A. F., Gallagher, J., Middleton, R. W., and Wright, J. The significance of "nonsignificance" in randomized controlled studies: a discussion inspired by a double-blinded study on St. John's wort (Hypericum perforatum L.) for premenstrual symptoms. J.Altern.Complement Med. 2004;10:925-932. View abstract.
  175. Pajonk, F., Scholber, J., and Fiebich, B. Hypericin-an inhibitor of proteasome function. Cancer Chemother.Pharmacol 2005;55:439-446. View abstract.
  176. Winkler, C., Wirleitner, B., Schroecksnadel, K., Schennach, H., and Fuchs, D. St. John's wort (Hypericum perforatum) counteracts cytokine-induced tryptophan catabolism in vitro. Biol.Chem 2004;385:1197-1202. View abstract.
  177. Kobak, K. A., Taylor, L. V., Warner, G., and Futterer, R. St. John's wort versus placebo in social phobia: results from a placebo-controlled pilot study. J.Clin Psychopharmacol. 2005;25:51-58. View abstract.
  178. Zhou, C., Tabb, M. M., Sadatrafiei, A., Grun, F., Sun, A., and Blumberg, B. Hyperforin, the active component of St. John's wort, induces IL-8 expression in human intestinal epithelial cells via a MAPK-dependent, NF-kappaB-independent pathway. J Clin.Immunol. 2004;24:623-636. View abstract.
  179. Uebelhack, R., Gruenwald, J., Graubaum, H. J., and Busch, R. Efficacy and tolerability of Hypericum extract STW 3-VI in patients with moderate depression: a double-blind, randomized, placebo-controlled clinical trial. Adv Ther. 2004;21:265-275. View abstract.
  180. Knuppel, L. and Linde, K. Adverse effects of St. John's Wort: a systematic review. J Clin.Psychiatry 2004;65:1470-1479. View abstract.
  181. Bjerkenstedt, L., Edman, G. V., Alken, R. G., and Mannel, M. Hypericum extract LI 160 and fluoxetine in mild to moderate depression: a randomized, placebo-controlled multi-center study in outpatients. Eur.Arch.Psychiatry Clin.Neurosci. 2005;255:40-47. View abstract.
  182. Schroeder, C., Tank, J., Goldstein, D. S., Stoeter, M., Haertter, S., Luft, F. C., and Jordan, J. Influence of St John's wort on catecholamine turnover and cardiovascular regulation in humans. Clin Pharmacol.Ther. 2004;76:480-489. View abstract.
  183. Volz, H. P. [Somatoform disorders--what must the general practitioner know?]. MMW.Fortschr.Med 8-19-2004;146(33-34):27-8, 30. View abstract.
  184. Trautmann-Sponsel, R. D. and Dienel, A. Safety of Hypericum extract in mildly to moderately depressed outpatients: a review based on data from three randomized, placebo-controlled trials. J Affect.Disord. 10-15-2004;82:303-307. View abstract.
  185. Stevinson, C. and Ernst, E. Can St. John's wort trigger psychoses? Int.J Clin.Pharmacol Ther. 2004;42:473-480. View abstract.
  186. Dona, M., Dell'Aica, I., Pezzato, E., Sartor, L., Calabrese, F., Della, Barbera M., Donella-Deana, A., Appendino, G., Borsarini, A., Caniato, R., and Garbisa, S. Hyperforin inhibits cancer invasion and metastasis. Cancer Res 9-1-2004;64:6225-6232. View abstract.
  187. Gelenberg, A. J., Shelton, R. C., Crits-Christoph, P., Keller, M. B., Dunner, D. L., Hirschfeld, R. M., Thase, M. E., Russell, J. M., Lydiard, R. B., Gallop, R. J., Todd, L., Hellerstein, D. J., Goodnick, P. J., Keitner, G. I., Stahl, S. M., Halbreich, U., and Hopkins, H. S. The effectiveness of St. John's Wort in major depressive disorder: a naturalistic phase 2 follow-up in which nonresponders were provided alternate medication. J.Clin Psychiatry 2004;65:1114-1119. View abstract.
  188. Gobbi, M., Moia, M., Funicello, M., Riva, A., Morazzoni, P., and Mennini, T. In vitro effects of the dicyclohexylammonium salt of hyperforin on interleukin-6 release in different experimental models. Planta Med 2004;70:680-682. View abstract.
  189. Muller, T., Mannel, M., Murck, H., and Rahlfs, V. W. Treatment of somatoform disorders with St. John's wort: a randomized, double-blind and placebo-controlled trial. Psychosom.Med. 2004;66:538-547. View abstract.
  190. Roder, C., Schaefer, M., and Leucht, S. [Meta-analysis of effectiveness and tolerability of treatment of mild to moderate depression with St. John's Wort]. Fortschr.Neurol.Psychiatr. 2004;72:330-343. View abstract.
  191. Werneke, U., Horn, O., and Taylor, D. M. How effective is St John's wort? The evidence revisited. J Clin.Psychiatry 2004;65:611-617. View abstract.
  192. Avato, P., Raffo, F., Guglielmi, G., Vitali, C., and Rosato, A. Extracts from St John's Wort and their antimicrobial activity. Phytother Res 2004;18:230-232. View abstract.
  193. Izzo, A. A. Drug interactions with St. John's Wort (Hypericum perforatum): a review of the clinical evidence. Int.J.Clin.Pharmacol.Ther. 2004;42:139-148. View abstract.
  194. Feisst, C. and Werz, O. Suppression of receptor-mediated Ca2+ mobilization and functional leukocyte responses by hyperforin. Biochem Pharmacol 4-15-2004;67:1531-1539. View abstract.
  195. Schule, C., Baghai, T., Sauer, N., and Laakmann, G. Endocrinological effects of high-dose Hypericum perforatum extract WS 5570 in healthy subjects. Neuropsychobiology 2004;49:58-63. View abstract.
  196. Wong, M. L., O'Kirwan, F., Hannestad, J. P., Irizarry, K. J., Elashoff, D., and Licinio, J. St John's wort and imipramine-induced gene expression profiles identify cellular functions relevant to antidepressant action and novel pharmacogenetic candidates for the phenotype of antidepressant treatment response. Mol.Psychiatry 1-13-2004; View abstract.
  197. Cui, Y., Ang, C. Y., Beger, R. D., Heinze, T. M., Hu, L., and Leakey, J. In vitro metabolism of hyperforin in rat liver microsomal systems. Drug Metab Dispos. 2004;32:28-34. View abstract.
  198. Simbrey, K., Winterhoff, H., and Butterweck, V. Extracts of St. John's wort and various constituents affect beta-adrenergic binding in rat frontal cortex. Life Sci. 1-9-2004;74:1027-1038. View abstract.
  199. Wright, C. W., Gott, M., Grayson, B., Hanna, M., Smith, A. G., Sunter, A., and Neill, J. C. Correlation of hyperforin content of Hypericum perforatum (St John's Wort) extracts with their effects on alcohol drinking in C57BL/6J mice: a preliminary study. J Psychopharmacol. 2003;17:403-408. View abstract.
  200. Kobak, K. A., Taylor, L., Futterer, R., and Warner, G. St. John's wort in generalized anxiety disorder: three more case reports. J Clin Psychopharmacol. 2003;23:531-532. View abstract.
  201. Franklin, M. Sub-chronic treatment effects of an extract of Hypericum perforatum (St. John's Wort, Li 160) on neuroendocrine responses to the 5-T2A agonist, DOI in the rat. Pharmacopsychiatry 2003;36:161-164. View abstract.
  202. Di Carlo, G., Nuzzo, I., Capasso, R., Sanges, M. R., Galdiero, E., Capasso, F., and Carratelli, C. R. Modulation of apoptosis in mice treated with Echinacea and St. John's wort. Pharmacol Res 2003;48:273-277. View abstract.
  203. Hostanska, K., Reichling, J., Bommer, S., Weber, M., and Saller, R. Hyperforin a constituent of St John's wort (Hypericum perforatum L.) extract induces apoptosis by triggering activation of caspases and with hypericin synergistically exerts cytotoxicity towards human malignant cell lines. Eur.J Pharm Biopharm. 2003;56:121-132. View abstract.
  204. Degar, S., Prince, A. M., Pascual, D., Lavie, G., Levin, B., Mazur, Y., Lavie, D., Ehrlich, L. S., Carter, C., and Meruelo, D. Inactivation of the human immunodeficiency virus by hypericin: evidence for photochemical alterations of p24 and a block in uncoating. AIDS Research and Human Retroviruses 1992;8:1929-1936. View abstract.
  205. Zullino, D. and Borgeat, F. Hypertension induced by St. John's Wort - a case report. Pharmacopsychiatry 2003;36:32. View abstract.
  206. Schempp, C. M., Winghofer, B., Muller, K., Schulte-Monting, J., Mannel, M., Schopf, E., and Simon, J. C. Effect of oral administration of Hypericum perforatum extract (St. John's Wort) on skin erythema and pigmentation induced by UVB, UVA, visible light and solar simulated radiation. Phytother Res 2003;17:141-146. View abstract.
  207. Lecrubier, Y., Clerc, G., Didi, R., and Kieser, M. Efficacy of St. John's wort extract WS 5570 in major depression: a double-blind, placebo-controlled trial. Am J Psychiatry 2002;159:1361-1366. View abstract.
  208. van Gurp, G., Meterissian, G. B., Haiek, L. N., McCusker, J., and Bellavance, F. St John's wort or sertraline? Randomized controlled trial in primary care. Can Fam Physician 2002;48:905-912. View abstract.
  209. Brenner, R., Madhusoodanan, S., and Pawlowska, M. Efficacy of continuation treatment with hypericum perforatum in depression. J Clin.Psychiatry 2002;63:455. View abstract.
  210. Behnke, K., Jensen, G. S., Graubaum, H. J., and Gruenwald, J. Hypericum perforatum versus fluoxetine in the treatment of mild to moderate depression. Adv Ther 2002;19:43-52. View abstract.
  211. Rychlik, R., Siedentop, H., von, den Driesch, V, and Kasper, S. [St. John's wort extract WS 5572 in minor to moderately severe depression. Effectiveness and tolerance of 600 and 1200 mg active ingredient daily]. Fortschr Med Orig. 11-29-2001;119(3-4):119-128. View abstract.
  212. Davidson, J. R. and Connor, K. M. St. John's wort in generalized anxiety disorder: three case reports. J.Clin.Psychopharmacol. 2001;21:635-636. View abstract.
  213. Jensen, A. G. and Hansen, S. H. Separation of hypericins and hyperforins in extracts of Hypericum perforatum L. using non-aqueous capillary electrophoresis with reversed electro-osmotic flow. J Pharm Biomed.Anal. 1-1-2002;27(1-2):167-176. View abstract.
  214. Guzelcan, Y., Scholte, W. F., Assies, J., and Becker, H. E. [Mania during the use of a combination preparation with St. John's wort (Hypericum perforatum)]. Ned.Tijdschr.Geneeskd. 10-6-2001;145:1943-1945. View abstract.
  215. los Reyes, G. C. and Koda, R. T. Development of a simple, rapid and reproducible HPLC assay for the simultaneous determination of hypericins and stabilized hyperforin in commercial St. John's wort preparations. J Pharm Biomed.Anal. 2001;26(5-6):959-965. View abstract.
  216. Pietta, P., Gardana, C., and Pietta, A. Comparative evaluation of St. John's wort from different Italian regions. Farmaco 2001;56(5-7):491-496. View abstract.
  217. Hunt, E. J., Lester, C. E., Lester, E. A., and Tackett, R. L. Effect of St. John's wort on free radical production. Life Sci 6-1-2001;69:181-190. View abstract.
  218. Brenner, R., Madhusoodanan, S., Pawlowska, M., and Czobor, P. St john's wort and major depression. JAMA 7-4-2001;286:43-45. View abstract.
  219. Fomous, C. M. and Cardellina, J. H. St John's wort and major depression. JAMA 7-4-2001;286:42-45. View abstract.
  220. Cott, J. M., Rosenthal, N., and Blumenthal, M. St John's wort and major depression. JAMA 7-4-2001;286:42-45. View abstract.
  221. Kalb, R., Trautmann-Sponsel, R. D., and Kieser, M. Efficacy and tolerability of hypericum extract WS 5572 versus placebo in mildly to moderately depressed patients. A randomized double-blind multicenter clinical trial. Pharmacopsychiatry 2001;34:96-103. View abstract.
  222. Ratz, A. E., von Moos, M., and Drewe, J. [St. John's wort: a pharmaceutical with potentially dangerous interactions]. Schweiz Rundsch.Med Prax. 5-10-2001;90:843-849. View abstract.
  223. Nathan, P. J. Hypericum perforatum (St John's Wort): a non-selective reuptake inhibitor? A review of the recent advances in its pharmacology. J Psychopharmacol. 2001;15:47-54. View abstract.
  224. Nangia, M., Syed, W., and Doraiswamy, P. M. Efficacy and safety of St. John's wort for the treatment of major depression. Public Health Nutr. 2000;3(4A):487-494. View abstract.
  225. Volp, A. Comparison of St John's Wort and imipramine. Sensitivity of assay is questionable. BMJ 2-24-2001;322:493-494. View abstract.
  226. Greeson, J. M., Sanford, B., and Monti, D. A. St. John's wort (Hypericum perforatum): a review of the current pharmacological, toxicological, and clinical literature. Psychopharmacology (Berl) 2001;153:402-414. View abstract.
  227. Alkhenizan, A. Comparison of St John's Wort and imipramine: Finding must be treated with caution. BMJ 2-24-2001;322:493. View abstract.
  228. Spira, J. L. Comparison of St John's Wort and imipramine. Study design casts doubt on value of St John's wort in treating depression. BMJ 2-24-2001;322:493. View abstract.
  229. Wonnemann, M., Singer, A., and Muller, W. E. Inhibition of synaptosomal uptake of 3H-L-glutamate and 3H-GABA by hyperforin, a major constituent of St. John's Wort: the role of amiloride sensitive sodium conductive pathways. Neuropsychopharmacology 2000;23:188-197. View abstract.
  230. Yu, P. H. Effect of the Hypericum perforatum extract on serotonin turnover in the mouse brain. Pharmacopsychiatry 2000;33:60-65. View abstract.
  231. Barbenel, D. M., Yusufi, B., O'Shea, D., and Bench, C. J. Mania in a patient receiving testosterone replacement postorchidectomy taking St John's wort and sertraline. J Psychopharmacol 2000;14:84-86. View abstract.
  232. Volz, H. P. and Laux, P. Potential treatment for subthreshold and mild depression: a comparison of St. John's wort extracts and fluoxetine. Compr.Psychiatry 2000;41(2 Suppl 1):133-137. View abstract.
  233. Di, Matteo, V, Di Giovanni, G., Di Mascio, M., and Esposito, E. Effect of acute administration of hypericum perforatum-CO2 extract on dopamine and serotonin release in the rat central nervous system. Pharmacopsychiatry 2000;33:14-18. View abstract.
  234. Stevinson, C. and Ernst, E. Hypericum for depression. An update of the clinical evidence. Eur Neuropsychopharmacol. 1999;9:501-505. View abstract.
  235. Grube, B., Walper, A., and Wheatley, D. St. John's Wort extract: efficacy for menopausal symptoms of psychological origin. Adv.Ther 1999;16:177-186. View abstract.
  236. Holsboer-Trachsler, E. and Vanoni, C. [Clinical efficacy and tolerance of the hypericum special extract LI 160 in depressive disorders--a drug monitoring study]. Praxis.(Bern.1994.) 9-9-1999;88:1475-1480. View abstract.
  237. Dimpfel, W., Todorova, A., and Vonderheid-Guth, B. Pharmacodynamic properties of St. John's wort-A single blind neurophysiological study in healthy subjects comparing two commercial preparations. Eur J Med Res 8-25-1999;4:303-312. View abstract.
  238. Josey, E. S. and Tackett, R. L. St. John's wort: a new alternative for depression? Int J Clin Pharmacol Ther 1999;37:111-119. View abstract.
  239. Kasper, S. Treatment of seasonal affective disorder (SAD) with hypericum extract. Pharmacopsychiatry 1997;30 Suppl 2:89-93. View abstract.
  240. Czekalla, J., Gastpar, M., Hubner, W. D., and Jager, D. The effect of hypericum extract on cardiac conduction as seen in the electrocardiogram compared to that of imipramine. Pharmacopsychiatry 1997;30 Suppl 2:86-88. View abstract.
  241. Sommer, H. and Harrer, G. Placebo-controlled double-blind study examining the effectiveness of an hypericum preparation in 105 mildly depressed patients. J Geriatr.Psychiatry Neurol. 1994;7 Suppl 1:S9-11. View abstract.
  242. Vorbach, E. U., Hubner, W. D., and Arnoldt, K. H. Effectiveness and tolerance of the hypericum extract LI 160 in comparison with imipramine: randomized double-blind study with 135 outpatients. J Geriatr.Psychiatry Neurol. 1994;7 Suppl 1:S19-S23. View abstract.
  243. Hänsgen, K. D., Vesper, J., and Ploch, M. Multicenter double-blind study examining the antidepressant effectiveness of the hypericum extract LI 160. J Geriatr.Psychiatry Neurol. 1994;7 Suppl 1:S15-S18. View abstract.
  244. Schulz, H. U., Schurer, M., Bassler, D., and Weiser, D. Investigation of the bioavailability of hypericin, pseudohypericin, hyperforin and the flavonoids quercetin and isorhamnetin following single and multiple oral dosing of a hypericum extract containing tablet. Arzneimittelforschung. 2005;55:15-22. View abstract.
  245. Soh, N. L. and Walter, G. Complementary medicine for psychiatric disorders in children and adolescents. Curr.Opin.Psychiatry 2008;21:350-355. View abstract.
  246. Schimmer, O., Hafele, F., and Kruger, A. The mutagenic potencies of plant extracts containing quercetin in Salmonella typhimurium TA98 and TA100. Mutat.Res 1988;206:201-208. View abstract.
  247. Sarris, J., Panossian, A., Schweitzer, I., Stough, C., and Scholey, A. Herbal medicine for depression, anxiety and insomnia: a review of psychopharmacology and clinical evidence. Eur.Neuropsychopharmacol. 2011;21:841-860. View abstract.
  248. Sarris, J. and Kavanagh, D. J. Kava and St. John's Wort: current evidence for use in mood and anxiety disorders. J.Altern.Complement Med. 2009;15:827-836. View abstract.
  249. Sarris, J., Kavanagh, D. J., Deed, G., and Bone, K. M. St. John's wort and Kava in treating major depressive disorder with comorbid anxiety: a randomised double-blind placebo-controlled pilot trial. Hum.Psychopharmacol. 2009;24:41-48. View abstract.
  250. van der Watt, G., Laugharne, J., and Janca, A. Complementary and alternative medicine in the treatment of anxiety and depression. Curr.Opin.Psychiatry 2008;21:37-42. View abstract.
  251. Jadad, A. R., Moore, R. A., Carroll, D., Jenkinson, C., Reynolds, D. J., Gavaghan, D. J., and McQuay, H. J. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin.Trials 1996;17:1-12. View abstract.
  252. Gurley, B. J., Fifer, E. K., and Gardner, Z. Pharmacokinetic herb-drug interactions (part 2): drug interactions involving popular botanical dietary supplements and their clinical relevance. Planta Med. 2012;78:1490-1514. View abstract.
  253. Unger, M. [Pharmacokinetic drug interactions by herbal drugs: Critical evaluation and clinical relevance]. Wien.Med.Wochenschr. 2010;160(21-22):571-577. View abstract.
  254. Izzo, A. A. and Ernst, E. Interactions between herbal medicines and prescribed drugs: an updated systematic review. Drugs 2009;69:1777-1798. View abstract.
  255. Laakmann, E., Grajecki, D., Doege, K., zu, Eulenburg C., and Buhling, K. J. Efficacy of Cimicifuga racemosa, Hypericum perforatum and Agnus castus in the treatment of climacteric complaints: a systematic review. Gynecol.Endocrinol. 2012;28:703-709. View abstract.
  256. van Die, M. D., Bone, K. M., Burger, H. G., Reece, J. E., and Teede, H. J. Effects of a combination of Hypericum perforatum and Vitex agnus-castus on PMS-like symptoms in late-perimenopausal women: findings from a subpopulation analysis. J.Altern.Complement Med. 2009;15:1045-1048. View abstract.
  257. van Die, M. D., Burger, H. G., Bone, K. M., Cohen, M. M., and Teede, H. J. Hypericum perforatum with Vitex agnus-castus in menopausal symptoms: a randomized, controlled trial. Menopause. 2009;16:156-163. View abstract.
  258. Briese V, Stammwitz U, Friede M, Henneicke-von Zepelin HH. Black cohosh with or without St. John's wort for symptom-specific climacteric treatment--results of a large-scale, controlled, observational study. Maturitas 2007;57:405-14. View abstract.
  259. Paris, A., Gonnet, N., Chaussard, C., Belon, P., Rocourt, F., Saragaglia, D., and Cracowski, J. L. Effect of homeopathy on analgesic intake following knee ligament reconstruction: a phase III monocentre randomized placebo controlled study. Br.J.Clin.Pharmacol. 2008;65:180-187. View abstract.
  260. Müller D, Pfeil T, von den Driesch V. Treating depression comorbid with anxiety--results of an open, practice-oriented study with St John's wort WS 5572 and valerian extract in high doses. Phytomedicine. 2003;10 Suppl 4:25-30. View abstract.
  261. Weber W, Vander Stoep A, McCarty RL, et al. Hypericum perforatum (St John's wort) for attention-deficit/hyperactivity disorder in children and adolescents: a randomized controlled trial. JAMA 2008;299:2633-41. View abstract.
  262. Wang LS, Zhu B, Abd El-Aty A, et al. The influence of St. John's wort on CYP2C19 activity with respect to genotype. J Clin Pharmacol 2004;44:577-81. View abstract.
  263. Samadi S, Khadivzadeh T, Emami A, et al. The effect of Hypericum perforatum on the wound healing and scar of cesarean. J Altern Complement Med 2010;16:113-7. View abstract.
  264. Booth JN, McGwin G. The association between self-reported cataracts and St. John's Wort. Curr Eye Res 2009;34:863-6. View abstract.
  265. Saito YA, Rey E, Almazar-Elder AE, et al. A randomized, double-blind, placebo-controlled trial of St. John's wort for treating irritable bowel syndrome. Am J Gastroenterol 2010;105:170-7. View abstract.
  266. Chung DJ, Kim HY, Park KH, et al. Black cohosh and St. John's wort (GYNO-Plus) for climacteric symptoms. Yonsei Med J 2007;48:289-94. View abstract.
  267. Obach RS. Inhibition of human cytochrome P450 enzymes by constituents of St. John's wort, an herbal preparation used in the treatment of depression. J Pharmacol Exp Ther 2000;294:88-95. View abstract.
  268. Fogle RH, Murphy PA, Westhoff CL, Stanczyk FZ. Does St. John's wort interfere with the antiandrogenic effect of oral contraceptive pills? Contraception 2006;74:245-8. View abstract.
  269. Bell EC, Ravis WR, Lloyd KB, Stokes TJ. Effects of St. John's wort supplementation on ibuprofen pharmacokinetics. Ann Pharmacother 2007;41:229-34. View abstract.
  270. Karalapillai DC, Bellomo R. Convulsions associated with an overdose of St John's wort. Med J Aust 2007;186:213-4. View abstract.
  271. Niederhofer H. St. John's wort may diminish methylphenidate's efficacy in treating patients suffering from attention deficit hyperactivity disorder. Med Hypotheses 2007;68:1189. View abstract.
  272. Jiang X, Blair EY, McLachlan AJ. Investigation of the effects of herbal medicines on warfarin response in healthy subjects: a population pharmacokinetic-pharmacodynamic modeling approach. J Clin Pharmacol 2006;46:1370-8. View abstract.
  273. Dugoua JJ, Mills E, Perri D, Koren G. Safety and efficacy of St. John's wort (hypericum) during pregnancy and lactation. Can J Clin Pharmacol 2006;13:e268-76. View abstract.
  274. Uebelhack R, Blohmer JU, Graubaum HJ, et al. Black cohosh and St. John's wort for climacteric complaints: a randomized trial. Obstet Gynecol 2006;107(2 Pt 1):247-55. View abstract.
  275. Dasgupta A, Hovanetz M, Olsen M, et al. Drug-herb interaction: effect of St John's wort on bioavailability and metabolism of procainamide in mice. Arch Pathol Lab Med 2007;131:1094-8. View abstract.
  276. Barnes J, Barber N, Wheatley D, Williamson EM. A pilot randomised, open, uncontrolled, clinical study of two dosages of St John's wort (Hypericum perforatum) herb extract (LI-160) as an aid to motivational/behavioural support in smoking cessation. Planta Med 2006;72:378-82. View abstract.
  277. Kobak KA, Taylor LV, Bystritsky A, et al. St John's wort versus placebo in obsessive-compulsive disorder: results from a double-blind study. Int Clin Psychopharmacol 2005;20:299-304. View abstract.
  278. Haller CA, Meier KH, Olson KR. Seizures reported in association with use of dietary supplements. Clin Toxicol (Phila) 2005;43:23-30. View abstract.
  279. Bryant SM, Kolodchak J. Serotonin syndrome resulting from an herbal detox cocktail. Am J Emerg Med 2004;22:625-6. View abstract.
  280. Linde K, Mulrow CD, Berner M, Egger M. St John's Wort for depression. Cochrane Database Syst Rev 2005;:CD000448. View abstract.
  281. Linde K, Knuppel L. Large-scale observational studies of hypericum extracts in patients with depressive disorders - a systematic review. Phytomedicine 2005;12:148-57. View abstract.
  282. Murphy PA, Kern SE, Stanczyk FZ, Westhoff CL. Interaction of St. John's Wort with oral contraceptives: effects on the pharmacokinetics of norethindrone and ethinyl estradiol, ovarian activity and breakthrough bleeding. Contraception 2005;71:402-8. View abstract.
  283. Lau WC, Carville DGM, Guyer KE, et al. St. John's Wort Enhances the Platelet Inhibitory Effect of Clopidogrel in Clopidogrel "Resistant" Healthy Volunteers. American College of Cardiology Annual Meeting, Orlando, FL 2005: Presentation 1043-129.
  284. Szegedi A, Kohnen R, Dienel A, Kieser M. Acute treatment of moderate to severe depression with hypericum extract WS 5570 (St John's wort): randomised controlled double blind non-inferiority trial versus paroxetine. BMJ 2005;330:503. View abstract.
  285. Shimizu K, Nakamura M, Isse K, Nathan PJ. First-episode psychosis after taking an extract of Hypericum perforatum (St John's Wort). Hum Psychopharmacol 2004;19:275-6. View abstract.
  286. Jiang X, Williams KM, Liauw WS, et al. Effect of St John's wort and ginseng on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Br J Clin Pharmacol 2004;57:592-9. View abstract.
  287. Komoroski BJ, Zhang S, Cai H, et al. Induction and inhibition of cytochromes P450 by the St. John's wort constituent hyperforin in human hepatocyte cultures. Drug Metab Dispos 2004;32:512-8. View abstract.
  288. Frye RF, Fitzgerald SM, Lagattuta TT, et al. Effect of St. John's wort on imatinib mesylate pharmacokinetics. Clin Pharmacol Ther 2004;76:323-9. View abstract.
  289. Hall SD, Wang Z, Huang SM, et al. The interaction between St John's wort and an oral contraceptive. Clin Pharmacol Ther 2003;74:525-35. View abstract.
  290. Pfrunder A, Schiesser M, Gerber S, et al. Interaction of St John's wort with low-dose oral contraceptive therapy: a randomized controlled trial. Br J Clin Pharmacol 2003;56:683-90. View abstract.
  291. Bilia AR, Gallori S, Vincieri FF. St. John's wort and depression: efficacy, safety and tolerability-an update. Life Sci 2002;70:3077-96. View abstract.
  292. Morimoto T, Kotegawa T, Tsutsumi K, et al. Effect of St. John's wort on the pharmacokinetics of theophylline in healthy volunteers. J Clin Pharmacol 2004;44:95-101. View abstract.
  293. Dean AJ, Moses GM, Vernon JM. Suspected withdrawal syndrome after cessation of St. John's wort. Ann Pharmacother 2003;37:150. View abstract.
  294. Siepmann M, Krause S, Joraschky P, et al. The effects of St John's wort extract on heart rate variability, cognitive function and quantitative EEG: a comparison with amitriptyline and placebo in healthy men. Br J Clin Pharmacol 2002;54:277-82. View abstract.
  295. Kim RB. Drugs as P-glycoprotein substrates, inhibitors, and inducers. Drug Metab Rev 2002;34:47-54. View abstract.
  296. Wilhelm KP, Biel S, Siegers CP. Role of flavonoids in controlling the phototoxicity of Hypericum perforatum extracts. Phytomedicine 2001;8:306-9. View abstract.
  297. Schule C, Baghai T, Ferrera A, Laakmann G. Neuroendocrine effects of Hypericum extract WS 5570 in 12 healthy male volunteers. Pharmacopsychiatry 2001;34:S127-33. View abstract.
  298. Shelton RC. St John's Wort for the treatment of depression. Lancet Neurol 2002;1:275.. View abstract.
  299. Draves AH, Walker SE. Analysis of the hypericin and pseudohypericin content of commercially available St John's Wort preparations. Can J Clin Pharmacol 2003;10:114-118.. View abstract.
  300. Foster BC, Vandenhoek S, Hana J, et al. In vitro inhibition of human cytochrome P450-mediated metabolism of marker substrates by natural products. Phytomedicine 2003;10:334-42.. View abstract.
  301. Gurley BJ, Gardner SF, Hubbard MA, et al. Cytochrome P450 phenotypic ratios for predicting herb-drug interactions in humans. Clin Pharmacol Ther 2002;72:276-87.. View abstract.
  302. Rayburn WF, Gonzalez CL, Christensen HD, Stewart JD. Effect of prenatally administered hypericum (St John's wort) on growth and physical maturation of mouse offspring. Am J Obstet Gynecol 2001;184:191-5. View abstract.
  303. Hammerness P, Basch E, Ulbricht C, et al. St. John's wort: a systematic review of adverse effects and drug interactions for the consultation psychiatrist. Psychosomatics 2003;44:271-82.. View abstract.
  304. Findling RL, McNamara NK, O'Riordan MA, et al. An open-label pilot study of St. John's wort in juvenile depression. J Am Acad Child Adolesc Psychiatry 2003;42:908-914.. View abstract.
  305. Hypericum Depression Trial Study Group. Effect of Hypericum perforatum (St. John's wort) in major depressive disorder: a randomized controlled trial. JAMA 2002;287:1807-14.. View abstract.
  306. Markowitz JS, Donovan JL, DeVane CL, et al. Effect of St. John's wort on drug metabolism by induction of cytochrome P450 3A4 enzyme. JAMA 2003;290:1500-4.. View abstract.
  307. Bauer S, Stormer E, Johne A, et al. Alterations in cyclosporin A pharmacokinetics and metabolism during treatment with St John's wort in renal transplant patients. Br J Clin Pharmacol 2003;55:203-11.. View abstract.
  308. Sugimoto K, Ohmori M, Tsuruoka S, et al. Different effects of St John's wort on the pharmacokinetics of simvastatin and pravastatin. Clin Pharmacol Ther 2001;70:518-24.. View abstract.
  309. Groning R, Breitkreutz J, Muller RS. Physico-chemical interactions between extracts of Hypericum perforatum L. and drugs. Eur J Pharm Biopharm 2003;56:231-6.. View abstract.
  310. Mai I, Stormer E, Bauer S, et al. Impact of St John's wort treatment on the pharmacokinetics of tacrolimus and mycophenolic acid in renal transplant patients. Nephrol Dial Transplant 2003;18:819-22.. View abstract.
  311. Logan JL, Ahmed J. Critical hypokalemic renal tubular acidosis due to Sjogren's syndrome: association with the purported immune stimulant echinacea. Clin Rheumatol 2003;22:158-9. View abstract.
  312. Anon. Final report on the safety assessment of Hypericum perforatum extract and Hypericum perforatum oil. Int J Toxicol 2001;20:31-9.. View abstract.
  313. Schwarz UI, Buschel B, Kirch W. Unwanted pregnancy on self-medication with St John's wort despite hormonal contraception. Br J Clin Pharmacol 2003;55:112-3. View abstract.
  314. Chan LY, Chiu PY, Lau TK. A study of hypericin-induced teratogenicity during organogenesis using a whole rat embryo culture model. Fertil Steril 2001;76:1073-4. View abstract.
  315. Wheatley D. Hypericum in seasonal affective disorder (SAD). Curr Med Res Opin 1999;15:33-7.. View abstract.
  316. Wang Z, Hamman MA, Huang SM, et al. Effect of St. John's wort on the pharmacokinetics of fexofenadine. Clin Pharmacol Ther 2002;71:414-20.. View abstract.
  317. Kasper S, Dienel A. Cluster analysis of symptoms during antidepressant treatment with Hypericum extract in mildly to moderately depressed out-patients. A meta-analysis of data from three randomized, placebo-controlled trials. Psychopharmacology (Berl) 2002;164:301-8.. View abstract.
  318. Ernst E. St. John's Wort supplements endanger the success of organ transplantation. Arch Surg 2002;137:316-9.. View abstract.
  319. Volz HP, Murck H, Kasper S, Moller HJ. St John's wort extract (LI 160) in somatoform disorders: results of a placebo-controlled trial. Psychopharmacology (Berl) 2002;164:294-300.. View abstract.
  320. Ladner DP, Klein SD, Steiner RA, Walt H. Synergistic toxicity of delta-aminolaevulinic acid-induced protoporphyrin IX used for photodiagnosis and hypericum extract, a herbal antidepressant. Br J Dermatol 2001;144:916-8. View abstract.
  321. Mathijssen RH, Verweij J, de Bruijn P, et al. Effects of St. John's wort on irinotecan metabolism. J Natl Cancer Inst 2002;94:1247-9.. View abstract.
  322. Schempp CM, Kirkin V, Simon-Haarhaus B, et al. Inhibition of tumour cell growth by hyperforin, a novel anticancer drug from St. John's wort that acts by induction of apoptosis. Oncogene 2002;21:1242-50.. View abstract.
  323. Henderson L, Yue QY, Bergquist C, et al. St John's wort (Hypericum perforatum): drug interactions and clinical outcomes. Br J Clin Pharmacol 2002;54:349-56.. View abstract.
  324. Calapai G, Crupi A, Firenzuoli F, et al. Serotonin, norepinephrine and dopamine involvement in the antidepressant action of hypericum perforatum. Pharmacopsychiatry 2001;34:45-9. View abstract.
  325. Bilia AR, Bergonzi MC, Morgenni F, et al. Evaluation of chemical stability of St. John's wort commercial extract and some preparations. Int J Pharm 2001;213:199-208. View abstract.
  326. Southwell IA, Bourke CA. Seasonal variation in hypericin content of Hypericum perforatum L. (St. John's Wort). Phytochemistry 2001;56:437-41. View abstract.
  327. Martonfi P, Repcak M, Ciccarelli D, Garbari F. Hypericum perforatum L. - chemotype without rutin from Italy. Biochem Syst Ecol 2001;29:659-61. View abstract.
  328. Kumar V, Jaiswal AK, Singh PN, Bhattacharya SK. Anxiolytic activity of Indian Hypericum perforatum Linn: an experimental study. Indian J Exp Biol 2000;38:36-41. View abstract.
  329. Irefin S, Sprung J. A possible cause of cardiovascular collapse during anesthesia: long-term use of St. John's Wort. J Clin Anesth 2000;12:498-9. View abstract.
  330. Holme SA, Roberts DL. Erythroderma associated with St John's wort. Br J Dermatol 2000;143:1127-8. View abstract.
  331. Hauben M. The association of St. John's wort with elevated thyroid-stimulating hormone. Pharmacotherapy 2002;22:673-5. View abstract.
  332. Ferko N, Levine MA. Evaluation of the association between St. John's wort and elevated thyroid-stimulating hormone. Pharmacotherapy 2001;21:1574-8 . View abstract.
  333. Singhal AB, Caviness VS, Begleiter AF, et al. Cerebral vasoconstriction and stroke after use of serotonergic drugs. Neurology 2002;58:130-3. View abstract.
  334. Patel S, Robinson R, Burk M. Hypertensive crisis associated with St. John's Wort. Am J Med 2002;112:507-8. View abstract.
  335. Parker V, Wong AH, Boon HS, Seeman MV. Adverse reactions to St John's Wort. Can J Psychiatry 2001;46:77-9. View abstract.
  336. Hennessy M, Kelleher D, Spiers JP, et al. St Johns wort increases expression of P-glycoprotein: implications for drug interactions. Br J Clin Pharmacol 2002;53:75-82. View abstract.
  337. Gorski JC, Hamman MA, Wang Z, et al. The effect of St. John's wort on the efficacy of oral contraceptives (abstract MPI-80). Clin Pharmacol Ther 2001;71:P25. View abstract.
  338. Schulz V. Incidence and clinical relevance of the interactions and side effects of Hypericum preparations. Phytomedicine 2001;8:152-60. View abstract.
  339. de los Reyes GC, Koda RT. Determining hyperforin and hypericin content in eight brands of St. John's wort. Am J Health Syst Pharm 2002;59:545-7. View abstract.
  340. Sultana D, Peindl KS, Wisner KL. Rash associated with St. John's wort treatment in premenstrual dysphoric disorder. Arch Women Ment Health 2000;3:99-101.
  341. Bhopal JS. St John's wort-induced sexual dysfunction. Can J Psychiatry 2001;46:456-457. View abstract.
  342. Mai I, Bauer S, Krueger H, et al. Wechselwirkungen von Johaniskraut mit tacrolismus bei nierentransplantierten patienten. Symposium Phytopharmaka VII. Forschung und Klinische Anwendung, Berlin, October, 2001.
  343. Mathijssen RHJ, Verweij J, De Bruijn P, et al. Modulation of irinotecan (CPT-11) metabolism by St. John's wort in cancer patients. American Association for Cancer Research Annual Meeting, San Francisco, April 2002. Abstract 2443.
  344. Sindrup SH, Madsen C, Bach FW, et al. St. John's wort has no effect on pain in polyneuropathy. Pain 2000;91:361-5. View abstract.
  345. Lal S, Iskandar H. St. John's wort and schizophrenia. CMAJ 2000;163:262-3. View abstract.
  346. Lane-Brown MM. Photosensitivity associated with herbal preparations of St. John's wort (Hypericum perforatum). Med J Aust 2000;172:302. View abstract.
  347. Wentworth JM, Agostini M, Love J, et al. St. John's wort, a herbal antidepressant, activates the steroid X receptor. J Endocrinol 2000;166:R11-6. View abstract.
  348. Vormfelde SV, Poser W. Hyperforin in extracts of St. John's wort (Hypericum perforatum) for depression [letter]. Arch Intern Med 2000;160:2548-9. View abstract.
  349. Cheng TO. St. John's wort interaction with digoxin [letter]. Arch Intern Med 2000;160:2548. View abstract.
  350. Moore LB, Goodwin B, Jones SA, et al. St. John's wort induces hepatic drug metabolism through activation of the pregnane X receptor. Proc Natl Acad Sci U S A 2000;97:7500-2. View abstract.
  351. Budzinski JW, Foster BC, Vandenhoek S, Arnason JT. An in vitro evaluation of human cytochrome P450 3A4 inhibition by selected commercial herbal extracts and tinctures. Phytomedicine 2000;7:273-82. View abstract.
  352. Barone GW, Gurley BJ, Ketel BL, et al. Drug interaction between St. John's wort and cyclosporin. Ann Pharmacother 2000;34:1013-6. View abstract.
  353. Woelk H. Comparison of St. John's wort and imipramine for treating depression: randomized controlled trial. BMJ 2000;321:536-9. View abstract.
  354. Stevinson C, Ernst E. A pilot study of Hypericum perforatum for the treatment of premenstrual syndrome. BJOG 2000;107:870-6. View abstract.
  355. Williams JW, Mulrow CD, Chiquette E, et al. A systematic review of newer pharmacotherapies for depression in adults: Evidence report summary. Ann Intern Med 2000;132:743-56. View abstract.
  356. Kleber E, Obry T, Hippeli S, et al. Biochemical activities of extracts from Hypericum perforatum L. 1st Communication: inhibition of dopamine-beta-hydroxylase. Arzneimittelforschung 1999;49:106-9. View abstract.
  357. Schempp CM, Winghofer B, Ludtke R, et al. Topical application of St. John's wort (Hypericum perforatum L.) and its metabolite hyperforin inhibits the allostimulatory capacity of epidermal cells. Br J Dermatol 2000;142:979-84. View abstract.
  358. Roby CA, Anderson GD, Kantor E, et al. St. John's wort: Effect on CYP3A4 activity. Clin Pharmacol Ther 2000;67:451-7. View abstract.
  359. Brenner R, Azbel V, Madhusoodanan S, et al. Comparison of an extract of Hypericum (LI 160) and sertraline in the treatment of depression: A double-blind, randomized pilot study. Clin Ther 2000;22:411-9. View abstract.
  360. Brown TM. Acute St. John's wort toxicity. Am J Emerg Med 2000;18:231-2. View abstract.
  361. Rey JM, Walter G. Hypericum perforatum (St. John's wort) in depression: pest or blessing? Med J Aust 1998;169:583-6. View abstract.
  362. Breidenbach T, Hoffmann MW, Becker T, et al. Drug interaction of St. John's wort with cyclosporin. Lancet 2000;355:1912. View abstract.
  363. Laird RD, Webb M. Psychotic episode during use of St. John's wort. J Herb Pharmacother 2001;1:81-7.
  364. Shelton RC, Keller MB, Gelenberg A, et al. Effectiveness of St. John's wort in major depression: A randomized, placebo-controlled trial. JAMA 2001;285:1978-86. View abstract.
  365. Snow V, Lascher S, Mottur-Pilson C. Pharmacologic treatment of acute major depression and dysthymia. Ann Intern Med 2000;132:738-42. View abstract.
  366. Taylor LH, Kobak KA. An open-label trial of St. John's wort (Hypericum perforatum) in obsessive-compulsive disorder. J Clin Psychiatry 2000;61:575-8. View abstract.
  367. Lantz MS, Buchalter E, Giambanco V. St. John's wort and antidepressant drug interactions in the elderly. J Geriatr Psychiatry Neurol 1999;12:7-10. View abstract.
  368. Ernst E, Rand JI, Barnes J, Stevinson C. Adverse effects profile of the herbal antidepressant St. John's wort (Hypericum perforatum L.). Eur J Clin Pharmacol 1998;54:589-94. View abstract.
  369. Linde K, Mulrow CD. St. John's wort for depression. Cochrane Database Syst Rev 2000;:CD000448. View abstract.
  370. Schrader E. Equivalence of St. John's wort extract (Ze 117) and fluoxetine: a randomized, controlled study in mild-moderate depression. Int Clin Psychopharmacol 2000;15:61-8. View abstract.
  371. Richter O. Several countries issue restrictions on St. John's wort. Richter's HerbLetter 7/30/00. Available at: www.richters.com (Accessed 01 March 2002).
  372. de Maat M, Hoetelmans R, Mathot R, et al. Drug interaction between St. John's wort and nevirapine. AIDS 2001;15:420-1. View abstract.
  373. Assalian P. Sildenafil for SJW-induced sexual dysfunction. J Sex Marital Ther 2000;26:357-8. View abstract.
  374. Wang Z, Gorski JC, Hamman MA, et al. The effects of St. John's wort (Hyericum perforatum) on human cytochrome P450 activity. Clin Pharmacol Ther 2001;70:317-26. View abstract.
  375. Mandelbaum A, Pertzborn F, Martin-Facklam M, Wiesel M. Unexplained decrease of cyclosporin trough levels in a compliant renal transplant patient. Nephrol Dial Transplant 2000;15:1473-4. View abstract.
  376. Karliova M, Treichel U, Malago M, et al. Interaction of Hypericum perforatum (SJW) with cyclosporin A metabolism in a patient after liver transplantation. J Hepatol 2000;33:853-5. View abstract.
  377. Moschella C, Jaber BL. Interaction between cyclosporine and Hypericum perforatum (St. John's wort) after organ transplantation. Amer J Kidney Dis 2001;38:1105-7. View abstract.
  378. Khalifa AE. Hypericum perforatum as a nootropic drug: enhancement of retrieval memory of a passive avoidance conditioning paradigm in mice. J Ethnopharmacol 2001;76:49-57. View abstract.
  379. Jacobson JM, Feinman L, Liebes L, et al. Pharmacokinetics, safety, and antiviral effects of hypericin, a derivative of St. John's Wort plant, in patients with chronic hepatitis C virus infection. Antimicrob Agents Chemother 2001;45:517-24. View abstract.
  380. Laakmann G, Dienel A, Kieser M. Clinical significance of hyperforin for the efficacy of Hypericum extracts on depressive disorders of different severities. Phytomedicine 1998;6:435-42.
  381. Shan MD, Hu LH, Chen ZL. Three new hyperforin Analogues from Hypericum perforatum. J Nat Prod 2001;664:127-30. View abstract.
  382. Schempp CM, Ludtke R, Winghofer B, Simon JC. Effect of topical application of hypericum perforatum extract on skin sensitivity to solar simulated radiation. Photodermatol Photoimmunol Photomed 2000;16:125-8. View abstract.
  383. Schempp CM, Muller K, Winghofer B, et al. Single-dose and steady-state administration of Hypericum perfotatum extract (St. John's wort) does not influence skin sensitivity to UV radiation, visible light, and solar-stimulated radiation. Arch Dermatol 2001;137:512-3. View abstract.
  384. Hubner WD, Kirste T. Experience with St. John's Wort (Hypericum perforatum) in children under 12 years with symptoms of depression and psychovegetative disturbances. Phytother Res 2001;15:367-70. View abstract.
  385. Jensen AG, Hansen SH, Nielsen EO. Adhyperforin as a contributor to the effect of Hypericum perforatum L. in biochemical models of antidepressant activity. Life Sci 2001;68:1593-605. View abstract.
  386. Jakovljevic V, Popovic M, Mimica-Dukic N, et al. Pharmacodynamic study of Hypericum perforatum L. Phytomedicine 2000;7:449-53. View abstract.
  387. Whiskey E, Werneke U, Taylor D. A systematic review and meta-analysis of Hypericum perforatum in depression: a comprehensive clinical review. Int Clin Psychopharmacol 2001;16:239-52. View abstract.
  388. Mai I, Kruger H, Budde K, et al. Hazardous pharmacokinetic interaction of Saint John's wort (Hypericum perforatum) with the immunosuppressant cyclosporin. Int J Clin Pharmacol Ther 2000;38:500-2. View abstract.
  389. Ondrizek RR, Chan PJ, Patton WC, King A. An alternative medicine study of herbal effects on the penetration of zona-free hamster oocytes and the integrity of sperm deoxyribonucleic acid. Fertil Steril 1999;71:517-22. View abstract.
  390. Ondrizek RR, Chan PJ, Patton WC, King A. Inhibition of human sperm motility by specific herbs used in alternative medicine. J Assist Reprod Genet 1999;16:87-91. View abstract.
  391. Peirce A. The American Pharmaceutical Association Practical Guide to Natural Medicines. New York, NY: William Morrow and Co., 1999.
  392. Markowitz JS, DeVane CL, Boulton DW, et al. Effect of St. John's wort (Hypericum perforatum) on cytochrome P-450 2D6 and 3A4 activity in healthy volunteers. Life Sci 2000;66:PL 133-9. View abstract.
  393. Gewertz N, Ereshefsky B, Lam YWF, et al. Determination of the differential effects of St. John's wort on the CYP1A2 and NAT2 metabolic pathways using caffeine probe methodology. Abstract Poster Presentations, 39th NCDEU Annual Meeting, 1999:Poster 131.
  394. Ereshefsky B, Gewertz N, Lam YMF, et al. Determination of SJW differential metabolism at CYP2D6 and CYP3A4, using dextromethorphan probe methodology. Abstract Poster Presentations, 39th NCDEU Annual Meeting, 1999:Poster 130 128.
  395. Beckman SE, Sommi RW, Switzer J. Consumer use of St. John's wort: A survey of effectiveness, safety, and tolerability. Pharmacotherapy 2000;20:568-74. View abstract.
  396. Moses EL, Mallinger AG. St. John's wort: Three cases of possible mania induction. J Clin Psychopharmacol 2000;20:115-7. View abstract.
  397. Nebel A, Schneider BJ, Baker RA, et al. Potential metabolic interaction between St. John's wort and theophylline. Ann Pharmacother 1999;33:502. View abstract.
  398. Nierenberg AA, Burt T, Matthews J, et al. Mania associated with St. John's wort. Biol Psychiatry 1999;46:1707-8. View abstract.
  399. Schempp C, Pelz K, Wittmer A, et al. Antibacterial activity of hyperforin from St. John's wort, against multiresistant Stapylococcus aureus and gram-positive bacteria. Lancet 1999;353:2129. View abstract.
  400. Singer A, Wonnemann M, Muller WE. Hyperforin, a major antidepressant constituent of St. John's wort, inhibits serotonin uptake by elevating free intracellular Na+1. J Pharmacol Exp Ther 1999;290:1363-8.. View abstract.
  401. Gaster B, Holroyd J. St John's wort for depression. Arch Intern Med 2000;160:152-6. View abstract.
  402. Philipp M, Kohnen R, Hiller KO. Hypericum extract versus imipramine or placebo in patients with moderate depression: randomized multicentre study of treatment for eight weeks. BMJ 1999;319:1534-9. View abstract.
  403. Harrer G, Schmidt U, Kuhn U, Biller A. Comparison of equivalence between the St. John's wort extract LoHyp-57 and fluoxetine. Arzneimittelforschung 1999;49:289-96. View abstract.
  404. Linde K, Ramirez G, Mulrow CD, et al. St. John's wort for depression: an overview and meta-analysis of randomized clinical trials. BMJ 1996;313:253-8. View abstract.
  405. Kim HL, Streltzer J, Goebert D. St. John's wort for depression: A meta analysis of well-defined clinical trials. J Nerv Ment Dis 1999;187:532-9. View abstract.
  406. Schempp CM, Winghofer B, Langheinrich M, et al. Hypericin levels in human serum and interstitial skin blister fluid after oral single-dose and steady state administration of Hypericum perforatum extract (St. John's Wort). Skin Pharmacol Appl Skin Physiol 1999;12:299-304. View abstract.
  407. Schneck C. St. John's wort and hypomania. J Clin Psychiatry 1998;59:689. View abstract.
  408. Roots I, Johne A, Schmider J, Brockmoller J, et al. Interaction of a herbal extract from St. John's wort with amitriptyline and its metabolites. Clin Pharmacol Ther 2000;67:159, abstract PIII-69.
  409. Lee A, Minhas R, Ito S, et al. Safety of St. John's wort during breastfeeding. Clin Pharmacol Ther 2000;67:130, abstract PII-64.
  410. Durr D, Stieger B, Kullak-Ublick GA, et al. St. John's Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4. Clin Pharmacol Ther 2000;68:598-604. View abstract.
  411. Gurley BJ, Gardner SF, Hubbard MA. Clinical assessment of potential cytochrome P450-mediated herb-drug interactions. AAPS Ann Mtg & Expo Indianapolis, IN: 2000; Oct 29 - Nov 2:presentation #3460.
  412. Gurley BJ, Barone GW. Herb-drug interaction involving St. John's wort and cyclosporine. AAPS Ann Mtg & Expo Indianapolis, IN:2000;Oct 29- Nov 2: presentation #3443.
  413. Roberts JE, Wang RH, Tan IP, et al. Hypericin (active ingredient in St. John's wort) photo-oxidation of lens proteins. Photochem Photobiol 1999;69:42S.
  414. Ruschitzka F, Meier PJ, Turina M, et al. Acute heart transplant rejection due to Saint John's wort. Lancet 2000;355:548-9. View abstract.
  415. Yue QY, Bergquist C, Gerden B. Safety of St. John's wort (Hypericum perforatum). Lancet 2000;355:576-7. View abstract.
  416. Piscitelli SC, Burstein AH, Chaitt D, et al. Indinavir concentrations and St John's wort. Lancet 2000;355:547-8. View abstract.
  417. Hussain MD, Teixeira MG. Saint John's wort and analgesia: effect of Saint John's wort on morphine induced analgesia. AAPS Ann Mtg & Expo Indianapolis, IN:2000;Oct 29- Nov 2:presentation #3453.
  418. Abul-Ezz SR, Barone GW, Gurley BJ, et al. Effect of herbal supplements on cyclosporine blood levels and associated acute rejection. Am Soc of Nephrol Ann Mtg, Toronto, CAN 2000;Oct. 11-16:abstract A3754.
  419. Muller WE, Singer A, Wonnemann M, et al. Hyperforin represents the neurotransmitter reuptake inhibiting constituent of hypericum extract. Pharmacopsychiatry 1998;31:16-21. View abstract.
  420. Chatterjee SS, Noldner M, Koch E, Erdelmeier C. Antidepressant activity of hypericum perforatum and hyperforin: the neglected possibility. Pharmacopsych 1998;31:7-15. View abstract.
  421. Laakmann G, Schule C, Baghai T, Kieser M. St. John's wort in mild to moderate depression: the relevance of hyperforin for the clinical efficacy. Pharmacopsych 1998;31:54-9. View abstract.
  422. Chavez ML, Chavez PI. Saint John's wort. Hosp Pharm 1997;32:1621-32.
  423. Upton R, ed. St. John's wort, Hypericum perforatum: Quality control, analytical and therapeutic monograph. Santa Cruz, CA: American Herbal Pharmacopoeia 1997;1-32.
  424. Brockmoller J, Reum T, Bauer S, et al. Hypericin and pseudohypericin: pharmacokinetics and effects on photosensitivity in humans. Pharmacopsychiatry 1997;30:94-101. View abstract.
  425. Bove GM. Acute neuropathy after exposure to sun in a patient treated with St. John's Wort. Lancet 1998;352:1121-2. View abstract.
  426. Golsch S, Vocks E, Rakoski J, et al. [Reversible increase in photosensitivity to UV-B caused by St. John's wort extract]. Hautarzt 1997;48:249-52. View abstract.
  427. Gordon JB. SSRIs and St. John's Wort: possible toxicity? Am Fam Physician 1998;57:950, 953. View abstract.
  428. Anon. A better treatment for depression? UC Berkeley Wellness Letter 1997;13:1-2.
  429. Johne A, Brockmoller J, Bauer S, et al. Pharmacokinetic interaction of digoxin with an herbal extract from St John's wort (Hypericum perforatum). Clin Pharmacol Ther 1999;66:338-45. View abstract.
  430. Hubner WD, Lande S, Podzuweit H. Hypericum treatment of mild depressions with somatic symptoms. J Geriatr Psychiatry Neurol 1994;7 Suppl 1:S12-4. View abstract.
  431. O'Breasail AM, Argouarch S. Hypomania and St John's wort. Can J Psychiatry 1998;43:746-7. View abstract.
  432. Gulick RM, McAuliffe V, Holden-Wiltse J, et al. Phase I studies of hypericin, the active compound in St. John's Wort, as an antiretroviral agent in HIV-infected adults. AIDS Clinical Trials Group Protocols 150 and 258. Ann Intern Med 1999;130:510-4. View abstract.
  433. Volz HP. Controlled clinical trials of hypericum extracts in depressed patients - an overview. Pharmacopsychiatry 1997;30 Suppl 2:72-6. View abstract.
  434. Wheatley D. LI 160, an extract of St. John's wort, versus amitriptyline in mildly to moderately depressed outpatients - a controlled 6-week clinical trial. Pharmacopsychiatry 1997;30:77-80. View abstract.
  435. Vorbach EU, Arnoldt KH, Hubner WD. Efficacy and tolerability of St. John's wort extract LI 160 versus imipramine in patients with severe depressive episodes according to ICD- 10. Pharmacopsychiatry 1997;30:81-5. View abstract.
  436. Bennett DA Jr, Phun L, Polk JF, et al. Neuropharmacology of St. John's Wort (Hypericum). Ann Pharmacother 1998;32:1201-8. View abstract.
  437. Miller LG. Herbal Medicinals: Selected clinical considerations focusing on known or potential drug-herb interactions. Arch Intern Med 1998;158:2200-11. View abstract.
  438. Murch SJ, Simmons CB, Saxena PK. Melatonin in feverfew and other medicinal plants. Lancet 1997;350:1598-9. View abstract.
Show more references
Show fewer references
Last reviewed - 05/30/2014




Page last updated: 08 September 2014